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1.HEAD AND NECK SQUAMOUS CELL CARCINOMA AND ORAL SQUAMOUS CELL 
CARCINOMA 
1.1. Definition 
The term head and neck cancer (HNC) defines a group of malignant cancers that arise in 
different anatomical districts in the region of the head and neck including oral cavity, 
pharynx and larynx.  
However different definitions have been proposed.  
For example the National Institute of Health, and more precisely, the National Cancer 
Institute reports that HNC correspond to “Cancer that arises in the head or neck region (in 
the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx).(1) Differently, UK’s 
National Health service describes HNC as a miscellaneous group of cancers from 30 
different organs or tissues in the head and neck region including “eye cancer, nasal and 
paranasal sinus cancer (cancers in the nasal cavity and in the sinuses around the 
nose),nasopharyngeal cancer (the area that connects the back of the nose to the back of 
the mouth), mouth and oropharyngeal cancer (cancers of the tongue, the gums, cheeks, lip 
and floor and roof of the mouth), larynx or laryngeal cancer (cancer of the voice box) and 
oesophageal cancer (cancer of the food pipe or gullet).”(2)  
Almost 90% of HNC are squamous cell carcinomas deriving from epithelial cells of mucosal 
upper digestive tract. 
Head and Neck Squamous Cell Carcinoma (HNSCCs) are strongly associated with tobacco 
exposure, alcohol, areca nut, low vitamins intake. 
Recently, also oncoviruses infection has been recognized as a risk factor for HNSCC 
development and in particular HPV 16,18, EBV, HHV-8.(3) 
 HNSCC usually adopts an aggressive clinical behaviour due to its ability to invade rapidly 
adjacent tissue and cervical lymph nodes.(4) 
Moreover, HNSCC local destructive action is linked to high risk of subsequent local relapses 
or distant lymph node metastasis  which comprises several demolitive surgeries.  
The tendency of multiple aggressive local or distant relapses is biologically explained by the 
theory of “field cancerization “. This theory was first proposed by Slaughter in 1953 and 
defines a genetically altered mucosal filed extended far beyond the border of the primary 
tumour, in which several squamous cell carcinomas may arise regardless surgical 
excision.(5) 
Treatment modalities include surgical excision of the neoplasia, associated to radiotherapy 
or adjuvant chemotherapy in advanced stages.  
Early diagnosis proved to impact positively overall survival and treatment efficacy. 
Nevertheless, despite clinical efforts in improving early diagnosis the survival rate hasn’t 
significantly improve in the last decade.(6)  
Therapy for HNSCC includes also the use of Cetuximab, a monoclonal antibody against 
Epidermal Growth Factor Receptor (EGFR) approved by the FDA (Food and Drug 
Administration).(7) 
 
 
1.2. Epidemiology: 
  
Incidence of HNSCC worldwide varies significantly depending on the anatomical site 
included in the statistics. On average, HNSCC classifies as the 6th  more common cancer 
accounting for 4,3 % of the tumours, 599.637 new cases and 224.834  new deaths each 
year. (Figure) 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
However, if squamous cell carcinoma of the upper 2/3 of the oesophagus was also included 
in the HNSCC group, incidence would rise sharply, classifying as the third more frequent 
carcinoma in men worldwide.  
  
As  far as oral squamous cell carcinoma ( OSCC) is concerned data estimates that 300000 
cases new cases per year and the mortality rate reaches levels  around 145 000 cases per 
year in Europe.(8) 
However, higher incidence levels occur in Asia and in particular in Melanesia and India. 
Widespread use of areca nut and betel leaves in these regions explains the results.  
FIG.1 The Graph shows the value of incidence 
(blue) and mortality(red) of Head and Neck Cancer 
worldwide. Left horizontal bars shows values for 
male population while right horizontal bars the 
values for women. Source: https://gco.iarc.fr/ 
Unfortunately, high incidence levels  of OSCC are followed by similar data on mortality. In 
Taiwan, for example, OSCC embodies the first cause of death among men aged 25-44 
years old. Low access to health services is a significant co-factor of high mortality in the 
region.(9) 
   
HNSCC incidence is greater in men. Lifestyle plays an important role in these findings. 
In fact, despite men are traditionally more exposed to well known risk factors for oral 
squamous cell carcinoma such as tobacco smoke or alcohol consumption, incidence of 
OSCC in women is increasing as effect of similar exposure to risk factors in both sexes. 
Additionally, deficit in estrogenic hormones has also been advocated to play a role in OSCC 
tumorigenesis. (10) 
 
OSCC tends to affect men in their sixth decade of life. Epidemiologic studies confirm worse 
trends in South Asia ( fifth decade of life ) with respect to North America  where  mean age 
of developing an OSCC stands above  the threshold of seventh and eighth decade of 
life.(11) 
However, recent data shows that the number of young patients affected by OSCC is 
increasing. So far, No scientific evidence seems to support that HPV is responsible for the 
increase of OSCC in young patients.  
Yet, HPV related OSCC show better responsiveness to therapies and better survival rates. 
(12) 
 
1.3. Risk Factors 
 
Tobacco smoke and alcohol abuse are major risk factors in OSCC development. Nearly 
80% of OSCCs seem to be related by the action of these two factors. Accordingly, 
suspension of tobacco or alcohol exposure would reduce approximately the incidence of 
OSCC by 80%.(13) 
Additional risk factors include viral agents ( i.e. HPV) chronic oral trauma, UV exposure and 
immunodepression. 
 
Tobacco:  
The risk of developing OSCC is 5-9 times greater in smokers with respect to non-smokers. 
OSCC risk is  dose-dependent. (14)The risk of developing OSCC  doubles if more of 20 
cigarettes/day are smoked.  Additionally, in patients who do not quit smoking after 
diagnosis, the risk of developing a second neoplasia after resective surgery is up to six 
times higher the risk of patients who quit.(15) 
Cancerogenetic action of tobacco smoke is mainly due to the presence of mutagenic 
compounds that can be found in products of combustion. More than 70 carcinogenetic 
compounds have been identified. 
These include : polycyclic aromatic hydrocarbons ( benzopyrene, anthracene) nitrosamines 
of tobacco ( N-nitrosonornicotine, N-nitrosodimethylamine ) aromatic amines (2-toluidine ), 
aldehydes ( formaldeyde) metals and organic compounds.(16) 
Direct termical irritation of tobacco smoke on mucosae seems to play an important role as 
co-factor.(17) In fact, reverse smoking, or the habit of smoking a cigarette with the lit end 
inside the mouth which is widespread in Andhra Pradesh and in Phylipinnes,correlates with 
higher risk of malignant transformation.(17) 
Tobacco exposure other than smoking is also related to OSCC development.  
For example, in India and South East Asia, the diffusion of chewing betel leaves in 
association with tobacco, areca nut and other irritating compounds not only induces the 
onset of submucous fibrosis, a pre-malignant lesion at high risk of cancer, but also reflects 
greater rates of OSCC incidence.(18) 
 
 
Alcohol 
  
Recent data indicate that  daily alcohol consumption exceeding 10g g/day cause negative 
effects on general health. Epidemiological data partially correlates an increase in HNSCC in 
young adults in UK with heavy alcohol drinkers.(19) 
Carcinogenetic effect of alcohol seems to synergic to tobacco smoking. In fact, the risk of 
OSCC in both heavy smokers and heavy drinkers appears to be 13 fold greater the risk of 
tobacco or alcohol considered independently.(20) 
 
 
Similar to tobacco smoking carcinogenetic action, also alcohol action seems  to be dose 
dependant in increasing  OSCC development . Alcohol abuse in the post-operative interval 
resulted in a significant reduction in survival rates, not necessarily related to disease 
relapses.(21) 
Experimental studies proved that ethanol acts  as a  mutagen as well as can act as solvent 
for other mutagens. Direct oncogenetic action seems to be related to acetaldehyde, one of 
the primary metabolites of alcohol and a powerful mutagen. (22,23) 
  
Fungal and viral infection 
 
Yeats and viruses have been investigated for years as potential triggers or co-factors of 
malignant transformation in OSCC.(24) 
In particular Candida spp. is able to produce powerful mutagens such as N-Nitroso 
bezilmetilamine which seems to play a pivotal role in cancer development. Candida spp. is 
also associated with premalignant lesions at moderate- high risk of evolving into OSCC 
such a hyperplastic chronic candidiasis.(25) 
However, neither Candida associated premalignant lesions nor the presence of Candida 
spp in samples from OSCC are able to differentiate between Candida direct carcinogenesis 
and Candida super-infection of premalignant/malignant lesions. (26)Consequently, role of 
Candida spp. in oral carcinogenesis are yet to be fully understood. 
HPV infection has been recently related to HNSCC development, and in particular 
genotypes  16 and HPV 18. HPV  has preferential tropism in the pharynx  where lymphoid 
tissue is abundant, and invasion of the mucosal barrier is easier. (26) 
In the oral cavity HPV associated OSCC tend to arise posteriorly, at the base of the tongue 
and in proximity to palatine tonsils while are far less frequent in the anterior part of the oral 
cavity.(27) 
Oncogenetic effect of HPV is mediated by HPV associated oncoproteins such as E6 and E7 
which can interfere with in many important pathways such as TP53 inducing tumoral  
degeneration.(28) 
 
UV radiations and immunodepression 
 
Long-time exposure to UV is a well-known risk factor for the development of OSCC of the 
lower lip.  
In the last years awareness of risk factors among general population has improved 
incidence rates for lip OSCC, whose prognosis is less aggressive than other OSCCs.(29) 
Immunodepression has a deep negative impact on tumorigenesis. As far as OSCC is 
concerned, bone marrow transplant and related immunosuppressant regimes expose the 
patient to a 6-10 folds higher risk of developing OSCC.(30) 
Similarly, HIV+  patients suffering from AIDS show and augmented risk of developing OSCC 
with respect to general population. 
In these patients immune system is compromised and tumours can escape immune 
surveillance more easily with more descriptive clinical effects.   (31) 
 
 
 
 
2. TNM CLASSIFICATION: 
 
TNM classification systems is based on the clinical extension of the disease and includes  
three parameters: dimension of primary tumour (T), nodal involvement (N), presence of 
distant metastasis (M). 
Clinical classification (cTNM) is based on data obtained before surgical treatment. After 
tumour resection,  cTNM is normally compared to histological classification ( pTNM). 
In HNSCC T parameter differs depending on the site of primary tumour. N classification of 
cervical nodes, on the contrary, is almost universal and only nodal involvement of 
nasopharynx has an independent classification.(32) 
 
TNM CLASSIFICATION TO DEFINE LIP AND ORAL CAVITY SQUAMOUS CELL 
CARCINOMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TAB1. The Table shows the criteria of  classification 
for  T category according to TNM classification. 
Source: AJCC 8th Edition 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TAB2. The Table shows the criteria of  classification 
for  N category according to TNM classification. 
Source: AJCC 8th Edition 
FIG.2 (left) The mesasure of depth of invasion  is assessed by dropping a 
“plumb line” from the horizon (level of basement membrane relative to the 
closest intact squamous mucosa)  
FIG.3 (right) Difference between “depth of invasion” ( blue bar) and tumour 
thickness (white bar)  
3. OSCC AND THE THEORY OF FIELD CANCERIZATION: 
3.1 Introduction: 
The term “ field cancerization” was introduced  by Slaughter and colleagues in 1953 (5) to 
explain the appearance of multiple  oral squamous cell carcinomas (OSCC)in the same 
patient. This model for head and neck cancer is still actual nowadays.  
3.2 Slaughter’s principles and first evidences. 
Analysing a population of 783 patients with OSCC  Slaughter  et al.(5) recorded in a 
publication titled “field cancerization  in oral stratified squamous epithelium. Clinical 
implications of multicentric origin” that 1) oral cancers usually had the tendency of spreading 
more easily in laterality than in depth 2) that the mucosa surrounding the neoplasia 
frequently harboured clinical or morphological atypia. 3) that OSCC may consist of multiple 
independent foci that eventually may converge 4) OSCC may develop multifocally in distant 
areas presenting preneoplatic features 5) the persistence of altered epithelium after surgical 
resection may induce the formation of new carcinomas. 
A similar apparently independent multifocality, they acknowledged, was “well above the 
statistical possibility of chance occurrence, therefore they concluded that multiple OSCC 
should be the effect of a “field cancerization,” in which an “area of epithelium has been 
preconditioned by an as-yet-unknown carcinogenic agent. Such a carcinogenic influence if 
operative long enough in time and intense enough in exposure produces an irreversible 
change in cells and cell groups in the given area, so that change of the process toward 
cancer becomes inevitable. “ 
Nowadays we know that not only was Slaughter’s intuition correct but also that it deeply 
helped our understanding of the natural history of OSCC. At that time, however, molecular 
techniques could hardly be performed hence it should not be surprising that a work citing 
the theory of field cancerization appeared no sooner than 16 years after Slaughter’s 
publication. 
In 1969 Roth et al (33) studying the healing performances of UV-induced damaged cells 
acknowledged that epithelium from patients affected by oral and upper aero digestive tract 
squamous cells carcinoma showed a reduced repairing ability. They reported that a similar 
deficit could be the result of a damage at DNA level predisposing for further tumour 
development. 
Albeit Slaughter’s theory had gained some clinical evidence it still lacked proper scientific 
basis and it could not gain widespread popularity.  
In 1982, Incze et al (34) observed, at electron microscope level, biopsies from normal 
appearing epithelium in patients with squamous cell carcinoma of the upper aero digestive 
tract and they reported that morphologic abnormalities were consistent with the concept that 
carcinogenesis is a multistep process of sequential neoplastic development extending over 
a long period of time.(Fig.1) 
Only two years later, in 1984, Strong et al (35) observed that Field cancerization could  be 
demonstrated by supravital staining with toluidine blue or by electron microscopic study of 
random biopsies taken from apparently normal mucosa. 
Both authors not only confirmed Slaughter’s statements with clinical and morphological 
means but also identified tobacco and alcohol exposure as the “yet-unknown carcinogenic 
agent” able to condition mucosal behaviour towards cancer development. 
3.3 Biomolecular evidences of Slaughter’s field cancerization  
In 1996 Califano et al(36), in response to the lack of knowledge surrounding   genetic 
progression  of head and neck squamous cell carcinoma and genetic basis for field 
cancerization, published a PCR based analysis of loss of heterozygosis  (LOH) at selective 
genes putatively involved in head and neck carcinogenesis. They studied a population of   
eighty-seven lesions of the head and neck, including pre-invasive lesions and benign 
lesions associated with carcinogen exposure. Observing the level of accumulation of gene 
losses at different degrees of pre-neoplastic lesions they found that it was possible to 
identify a model that could explain the progression of a mutated epithelium towards 
squamous cell carcinoma. However, despite some mutations were more likely to occur at 
specific stages or pre-malignancy, they suggested that accumulation rather than the order 
of genetic events led mutated cells in the progression towards cancer. 
Genes studied by Califano and colleagues(36) included the 9p21 locus corresponding  to an 
area of genetic loss common to many solid tumours containing p16, a cyclin-dependent 
kinase inhibitor involved in cell cycle regulation. Region 11q13 that includes the bcl-1/int-2 
locus, an amplicon carrying the proto-oncogene cyclin D1, the p53 gene locus  located at 
17p13, the 3p21 locus and 13q21 locus that  contains an area with frequent LOH near the 
retinoblastoma locus(36). 
In particular, 3p and 17p losses were more frequent in mucosa undergoing dysplastic 
modification while 11q and 13 q losses could be found in epithelium preceding malignant 
transformation. 
Califano’s results were confirmed by Patridge et al.  in 1997 (37) and  Lydiatt(38,39) in 1998  
where LOH  was found in dysplastic tissue surrounding tumours and   histologically normal 
mucosa respectively. 
Genetic approach paved the way to a large number of studies with different molecular 
techniques that tried to disclose hidden mechanisms of oral carcinogenesis with the aim at 
discovering clinically relevant biomarkers to be used in clinical practice. 
As a consequence, the extension of the field and the related premalignant lesion whence 
the field could have been arisen, became a major concern. 
Noteworthy, Ai H. (39) in 1999 detected by FISH  chromosome aneuploidy in mucosa 
distant from the carcinoma.  Interestingly, 9/10 tested patients were smokers with respect to 
only one non-smoker patient with aneuploidy. Molecular tests can be of difficult application 
in daily practice, therefore several authors tested immunohistochemical markers useful to 
evidence areas od filed cancerization. 
Van Oijen e Slootweg in  2000 (40)demonstrated that immunostaining of P53 and  EGFR 
was abnormal in apparently normal mucosa of smokers when compared to non-smokers 
subjects. (Fig.2) 
Tabor et al. (41)demonstrated that the presence of Ki67 positive mature keratinocytes , 
corresponded to areas of LOH. This observation has been validated by Montebugnoli et 
al(42–44)who demonstrated that the immunohistochemical  analysis of ki67  in oral mucosa 
located in the cheek opposite to the OSCC can act as prognostic biomarker as, when 
overexpressed, had an impact on the aggressiveness of the primary tumour. 
On the other hand, studies speculated on how far the field could extend. Interestingly 
Griffioen GH, et al.(45) In 2015 reported that patients successfully treated for head and neck 
cancer died of primary lung cancers suggesting that the field could extend not only through 
the entire upper aero digestive tract, but also in the deep respiratory system.(Fig.3) 
 
3.4 Multiple Oral Lesions: Different models for field cancerization and the problem of 
clonality  
The theory of field cancerization derives from the effort of explaining the increased 
occurrence of local secondary tumours in oral cavity and upper aero digestive tract. 
However, the exact mechanisms through which this phenomenon occurs are still matters of 
debate and different theories has been formulated so far. 
In 1999 Garcia et al (46)described the presence  of cluster of cells usually positive for TP53 
in the normal mucosa of patients with head and neck squamous cell carcinoma. He called 
these clusters “patches”. 
Assuming a monoclonal origin for oral squamous carcinoma, he hypothesized that these 
clusters of genetically altered cells could clonally expand as a consequence of proliferative 
advantages over non mutated cells generating greater area of mutated mucosa, better 
defined as “field”. Hence, according to Califano’s  model of carcinogenesis(47), the 
accumulation in the field of further mutations could  lead to the development of independent 
neoplastic events.  
On the other hand, an alternative theory reviewed by van Oijen et al.  in 2000(40), reported 
that   the occurrence of  multiple pre(neoplastic) events could also  result from a migration of 
mutated cells that, acting as micro metastasis, could generate different tumours at different 
local sites. 
Apart from field cancerization theoretical models, the distinction between a local recurrence 
(LR) a metastasis or a second primary tumour (SPT) always represented a critical clinical 
issue able to deeply influence therapy and prognosis.  
Before genetic approach, Second Primary Tumours (SPT) were usually defined by  many 
researchers using  Warren and Gates(48) criteria developed in 1932. This method was 
based on clinical and morphological parameters. In particular, SPTs were defined as two 
neoplastic lesions showing definitive and distinct pictures of malignancies after excluding 
that one could be the metastasis of the other. However, in case of two lesions both in the 
same anatomical area, the minimal distance to exclude a local recurrence was controversial 
as some researchers accepted 2 cm while others 1.5 cm. 
Furthermore, second events may chronologically develop synchronously or 
methachronously depending on whether the interval between the two carcinomas is lower or 
higher than six months respectively. Similarly, to spatial criteria, also time of occurrence 
could easily be confounding in the diagnosis of a second event. 
As aforementioned criteria were easily matter of debate and scarcely  took  into account the 
theory of field cancerization, in 2002 Braakhuis (49), proposed a modification based on 
genetic profiles.  
Evidence deriving from many works on LOH and TP53 mutations led Braakhuis to identify 
four types of second events: Local recurrence, metastasis, second primary tumours and 
second field tumours. 
In particular, common molecular profiles between the primary tumours and the second 
lesions should be interpreted as consistent with local recurrence or metastasis depending if 
the second event developed in adjacent or distant site respectively. On the other hand, 
partially different genetic profile between the two lesions, should be suggestive of a 
secondary field tumour that, arising from a preconditioned field but followed different 
carcinogenetic pathways. Second Primary Tumours, being genetically and clinically 
independent should instead show different genetic profiles. 
Further studies(50–53) confirmed the utility of Braakhius modified criteria and disclosed new 
genetic methodologies to perform clonal analysis of multiple squamous cell carcinomas.  
Remarkably, the high frequency rate of mtDNA mutations in tumors, especially those found 
in the D-loop region, a non-coding region, along with numerous mitochondrial genomes 
present in a single cell, has made  mtDNA a reliable marker for clonality assays from 
microdissected paraffin-embedded tissue samples. (54,55)  
As a result, mtDNA analysis not only demonstrated higher diagnostic sensibility when 
compared to clinical and temporal criteria, but also resulted more informative with respect to 
TP53 analysis, reflecting the ability of some squamous cell carcinoma to follow carcinogenic 
pathways different from TP53 mutations. 
In addition, mtDNA analysis resulted highly useful in disclosing possible mechanisms 
behind the cancerization of skin graft after surgery such as the spread of the clonal cell 
population to the cutaneous flap stimulated by cytokines produced by the grafted skin. 
 In fact, as reported by Foschini et al,(50) in all three studied  cases, the neoplastic lesions 
arising in the skin graft showed a clonal relationship with the previous OSCC and, on the 
basis of the results obtained by mtDNA analysis, could be considered as a recurrence of the 
primary OSCC.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG.3: Apparently normal oral mucosa can present 
small areas of altered epithelial keratinocytes 
 
FIG.4: Immunohistochemical staining for TP53 in a 
restricted “patch” of oral epithelium supports the 
theory according to which the progression of a field of 
genetically altered kerationcytes precedes and 
promotes oral carcinogenesis 
 
FIG 5: Smokers can present small areas of dysplasia in 
bronchial epithelium 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. THE CONCEPT OF INTRATUMORAL HETEROGENEITY: 
 
Introduction 
The idea of heterogeneity among tumours and within tumours is not new. The observation 
that microscopic morphology may not be uniform throughout the entire extension of  a 
primary tumor suggested that differences may exist among tumours cells. 
Slaughter et al, studying morphology of OSCC recorded that OSCC may consist of multiple 
independent foci that eventually may converge. (5) 
In addition, the hypothesis of tumoral heterogeneity was supported by clinical data even 
before bimolecular investigations, as tumours with similar morphology but deeply different  
behaviour and prognosis. 
However, only in recent years, thank to improved sequencing technologies it was possible 
to study tumor heterogeneity at a deeper level. 
Tumours should thus be regarded as complex biological entities. Heterogeneity seems to 
involve  clinical, phenotypic, genetic and epigenetic variables as disclosed by recent studies 
of molecular biology applied to tumours.  
Two theories have been proposed to explain intratumour heterogeneity: clonal evolution 
models and cancer stem cells models (CSC).(56,57) 
FIG 6: According to field cancerization theory three 
different types of  second events can develop after 
primary tumour resection: Local Recurrence, Second 
Primary tumour and second field tumour. Source: 
https://www.tandfonline.com/doi/pdf/10.1586/1473715
9.2016.1126512 
 
Both theories assume that tumours are initiated by single cells that acquire molecular 
aberrations that confer on them proliferative advantages and escape from programmed 
death and believe that microenvironment plays an important role in tumor progression. 
Nevertheless, the two theories also display important differences. 
 
4.1 Clonal evolution theory: 
In 1976 Nowell proposed a theory of clonal evolution assuming that a single cell could give 
rise to a tumor through a continued accumulation of genetic mutations.(58) 
Genetic instability could then result in progressive formation  of clonal populations 
contributing to intra-tumor heterogeneity. 
Two types of clonal evolution have been described : linear and branched evolution. 
In linear evolution  mutations are sequential and fitter clones tend to replace their 
predecessors. The grade of heterogeneity in linear evolution is low and can be observed 
only when new clones has only partially replaced the old ones. 
Linear evolution has been observed in acute myeloid leukaemia and multiple myeloma. 
In the branched evolution theory, different subclones coexist and evolve as the branches of 
a tree. 
Early mutations, being shared by all subclones, can be seen as the trunk of the tree and 
reflect the genetic profile of the founder cell. During the evolution, genetic instability induces 
the formation of new subclones who acquire new genetic features. 
Clonal evolution, due to its branching evolution, reflects higher grade of heterogeneity. 
However, it is important to mention that proliferation and expansion of a given subclone is 
the result of selective pressures that follow  Darwinian rules.  
 
 
 
4.2 Cancer stem cell theory: 
This theory claims that only a small amount of cells with great self renewal ability features 
has the potential to promote tumor progression. These cells are cancer-stem-cells (CSCs) 
When CSCs lose their “stemness” and differentiate into a non CSC phenotype they give rise 
to subclones with individual genetic profile contributing to intratumor heterogeneity. 
The CSC theory was firs demonstrated in hematopoietic tumours and later in solid tumours. 
A set of membrane surface markers permits to identify CSCs ( i.e CD44+ /CD 24 low).(59) 
Experimental studies demonstrate that cell with CSCs profiles can be isolated and if injected 
in xenografts are able to induce tumor formation and progression. 
CSCs divide asymmetrically, resulting in a self-renewal CSC and a non.CSC. Non CSCs 
represent the majority of tumor mass but contribute less to tumor proliferation.(60) 
Interestingly, according to CSC model, tumor cells show cellular plasticity. In fact, not only 
CSC may differentiate into non.CSC but also a non-CSC may reversibly switch to a CSC 
particular conditions.(61) 
Tumor biology is thus regulated not only through a hierarchic organization of cells ( with and 
without self-renewal ability) but also by a homeostatic equilibrium between CSCs and non 
CSCs.(62) 
Cancer stem cell model has gained increasing attention in recent years and studies have 
tried to study CSC markers in both OSCC and adjacent mucosa. The goal was to integrate 
our understanding  of OSCC biology with evidence that markers associated with a stem-cell 
like behaviour. 
Noteworthy, Simple et et al have proposed an intriguing theoretical model for field 
cancerization driven by genetically mutated stem-cells. In particular, according to that 
model, field cancerization is initiated by the carcinogen assault leading to genetic mutations 
(p53/p16) in a stem cell residing in normal epithelium. This cancer stem cell will proliferate 
and initially form a patch), which ultimately spreads to form a field. Histologically, at this 
stage the cells remain in dysplastic or a premalignant stage. After getting a subsequent hit 
(RB), one of the cells in the field will form the primary tumor. The tumor will also host the 
increase in expression of different CSC-specific genes and other downstream markers of 
HNSCC tumorigenesis.  
The progression of the field occurs either by the monoclonal or the polyclonal mode of 
cancerization. The CSCs of the field can also migrate (CD44h/ALDH1A1h) laterally to 
spreadthe field or get implanted at a new site and form a genetically similar tumor at a later 
stage signifying the monoclonal mode of field cancerization. On the other hand, multiple hits 
to the normal stem cells in the epithelium will lead to the development of independent 
clones (polyclonal mode). (63) 
Nevetheless, as pointed out by Gonzales-Moles et al, results are divergent depending on 
which marker of CSC is used. Hence, the search for specific markers to identify these cells 
in routine laboratory workup are strongly encouraged.(64) 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 7 Stochastic model and CSC model describe 
different patterns of tumour evolution but both include 
the formation of genetic  heterogeneity among tumour 
cells.Source: www.nature.com/articles/nrc3597 
 
EXPERIMENTAL SECTION: 
 
1. AIMS OF THE PHD PROJECT (ABSTRACT): 
Worldwide high mortality rate of Oral squamous cell carcinoma (OSCC) gives rise to a 
considerable global public health burden (65). Despite the currently available therapeutic 
strategies, comprising the surgical excision of malignant tissue and a combination of 
radiotherapy and chemotherapy, the 5-year survival rate is still poor (66). The high mortality 
rate is usually attributed to late diagnosis, but some cases of OSCC surgically treated at an 
early stage still present with aggressive behaviour and disease progression (67,68) The 
aggressive behaviour of OSCC has been related to the “field cancerization concept” as the 
mucosa surrounding the primary mass is characterized by genetically altered epithelial cells 
that can escape clinical and histological examination and that may be responsible for cancer 
progression(69). 
Recently, also the existence of  a heterogeneous population of cells within the tumour mass 
(intratumor heterogeneity)  has been linked to tumour aggressiveness and resistance to 
therapy. 
Therefore, current research efforts focus on the discovery of new therapeutic strategies to 
determine the risks of OSCC occurrence, progression, and metastatic spread, and thereby 
to reduce mortality rates. Aim of the present PhD project was to investigate  field 
cancerization and intratumour heterogeneity in OSCC adopting a biomolecular approach. 
 
 
 
 
 
PROJECT 1: INVESTIGATION OVER IMMUNOHISTOCHEMICAL EXPRESSION OF KI67 
IN DISTANT MUCOSAE AS A PROGNOSTIC FACTOR IN ORAL SQUAMOUS CELL 
CARCINOMA (PUBBLISHED AS: Ki67 Overexpression in mucosa distant from oral carcinoma: A poor 
prognostic factor in patients with long-term follow-up, Journal of Cranio-Maxillofacial Surgery, Volume 44, 
Issue 9, September 2016, Pages 1430-1435) 
 
 
AIMS : 
Genetically altered cells may escape macroscopic or histopathological examination and 
may require sophisticated biomolecular approaches to investigate genetic abnormalities of 
the epithelial  field surrounding the tumor.(41,70–72). Immunohistochemistry is a simple, 
low-cost procedure that is frequently used to improve histological diagnosis. The Ki67 index 
is a good predictor of the presence of genetically altered cells in oral mucosa (41,73–76) 
and a good surrogate of sophisticated analyses, i.e., loss of heterozygosity (LOH)(41) when 
applied to the “non-neoplastic” mucosa surrounding a primary OSCC. 
Aim of this project was to investigate   whether Ki67 in distant mucosa from a long-term 
follow-up data from a cohort of patients treated for OSCC is associated with a poor 
prognosis in terms of locoregional control (LRC) of disease (appearance of local recurrence, 
second primary tumor, and lymph node metastasis) and disease-specific survival (DSS). 
 
 METHODS 
Patients and procedures 
The studied population consisted of 55 patients with a histological diagnosis of OSCC 
referred to our Department with a minimum of 12 months follow-up. The diagnosis and 
surgical treatment of OSCC were performed at the Department of Biomedical and 
Neuromotor Sciences University of Bologna, Sections of Oral Sciences, Anatomic 
Pathology at Bellaria Hospital and the Maxillofacial Surgery Unit, Sant'Orsola Hospital. 
Patient assessment at presentation, before surgery, included examination and diagnostic 
imaging (head and neck computed tomography [CT] scan and/or magnetic resonance 
imaging [MRI]). Patient treatment consisted of a composite resection, including excision of 
the primary tumor with ipsilateral or bilateral neck dissection. Selective supraomohyoid neck 
dissection with lymph node evaluation on frozen sections was performed simultaneously 
with tumor resection in all cases diagnosed as cN0. If a lymph node metastasis was 
disclosed on frozen section, the neck dissection was extended to levels IV and V. Radical or 
modified radical neck dissection was performed for stage cNþ patients. During surgery, a 
specimen of macroscopically non-neoplastic mucosa was removed from the cheek opposite 
the primary OSCC for immunohistochemical evaluation of Ki67. 
The work was approved by the ethical committee of the University of Bologna and all 
patients gave their written informed consent (CH-MAX-HNC Markers code 
037/2008/O/Tess). The cohort of the present study included some of the patients analysed 
in previous studies(42,77)  
Adjuvant therapy was administered according to the National Comprehensive Cancer 
Network guidelines(78) in locally advanced T3 and T4 lesions, lesions with high-grade 
histology or positive or close to the margins of surgical resection, and in cases with an N-
stage higher than N1. 
Follow-up was performed every 2 weeks for the first 2 months after surgery and then 
monthly during the first year after surgery, every 3 months during the second year after 
surgery, and finally every 6 months. A CT scan or MRI was requested every 6 months 
during the first 3 years after surgery and then once a year. Clinicopathological information 
obtained from each patient included: age; sex; tumor location; tumor stage, according to the 
TNM classification of the International Union Against Cancer(79); CT and clinical 
examination before surgical management to identify all patients with clinically positive 
cervical lymph node metastasis (LNM) using criteria defined in(80); histological grade, 
defined according to(65); status of surgical margins assessed at the closest point to the 
surgical resection margin and classified in four categories according to the guidelines of the 
Royal College of Pathologists in the United Kingdom(81) as follows: 
▪ cleared no evidence of microscopic carcinoma or presence of epithelial precursor lesions 
(EPLs) within 5 mm of the margin 
▪ closed histological evidence of carcinoma between 5 and 1 mm of the margin but not at 
the margin 
▪ involved when neoplastic cells appeared on the inked margin (cases with involved margin 
were excluded from the present study) 
▪ EPL of moderate-to-severe dysplasia (high grade squamous intra-epithelial lesions 
according to the Ljubljana classification) or in situ carcinoma (82) but not invasive 
carcinoma within 5 mm of the margin.  
Ki-67 expression was evaluated in each patient from both the biopsy samples obtained 
within the tumor mass and the clinically non-neoplastic mucosa located in the cheek 
opposite the primary OSCC. No distant site showed any sign of premalignant 
transformation. 
All areas in the opposite cheek chosen for the biopsy sample were free of any trauma or 
clinically visible abnormal condition. All tissues were fixed in 10% formalin and embedded in 
paraffin according to routine practice. Serial sections were cut from each block and stained 
with hematoxylin and eosin for histologic evaluation and immunohistochemical analysis 
using the anti-Ki-67 monoclonal antibody (clone MIB 1, diluted 1:200 Dako, Glostrup, 
Denmark). The processing was performed in an automatic stainer 
(Autostainer, Ventana Medical Systems, Tucson, AZ, USA). Counting the percentage of 
positive nuclei in 400 consecutive epithelial cells from selected areas yielded a 
semiquantitative evaluation of the immunohistochemical results. In addition, the presence of 
mature 
keratinocytes positive for Ki67 was recorded. Cut-off values of Ki67-positive cells of 42% in 
OSCC and 20% in non-neoplastic mucosa served to separate cases with “high” and “low” 
proliferative indexes(42,77) . These cut-off values in normal tissue were taken as reference 
according to previous works and were based on literature validated data.  All slides were 
evaluated by a pathologist who was unaware of the clinical and follow-up information. The 
mucosal biopsy obtained from the cheek opposite to the OSCC was evaluated for the 
presence of oral potentially malignant lesions, which were reviewed and graded according 
to the recently proposed Ljubljana system(82) The disease-free survival endpoints were 
defined as the duration between treatment completion and the diagnosis of recurrence, 
lymph node or distant metastasis, death, or the last follow-up visit. 
Statistical analysis  
The outcomes of interest of the present study were disease specific survival (DSS) and 
locoregional control (LRC). DSS was defined as the time from diagnosis of the primary 
tumor to death from OSCC; LRC was defined as time from OSCC diagnosis to appearance 
of local recurrence (LR), second primary tumor (SPT), or LNM. The patient's age, sex, 
primary localization, T score, clinical staging, lymph node at appearance, tumor stage, 
histological grade, status of surgical margins, perineural and vascular invasion, Ki67 within 
tumor mass, and Ki67 from distant mucosa were analysed for their relationship to DSS and 
LRC. The survival rate was estimated using the Kaplan Meier method. Statistical 
significance was evaluated using the log-rank test. For those variables found to be 
statistically significant by univariate analysis, the Cox proportional hazards method with 
forward selection was used for further evaluation by multivariate survival analysis. Time was 
defined as the period between treatment and the target event (DSS or LRC) or last follow-
up. P values <0.05 were considered to be statistically significant in all analyses.  
 
 
 RESULTS 
Descriptive analysis 
A total of 55 cases met the inclusion criteria. Of the 55 patients, 32 were male and 23 were 
female, with a median age of 61.9 ± 16.1 
years. Index tumor locations were the following: in 24 of 55 patients, the tongue; in 9, the 
floor of mouth; in 9, the cheek; in 1, the soft palate; in 11, the gingival and hard palate; and 
in 1, the lower lip. In all, 46 patients were treated with surgery alone, and 9 patients were 
treated with adjuvant radiotherapy. All disease-free patients had a minimum of 12 months' 
follow-up (mean 53.7 ± 32.4 months; range 12e110 months). During the follow-up, 23 of 55 
patients (41.8%) experienced a second locoregional neoplastic manifestation: 6 of 55 
(10.9%) developed an LR, 12 (21.8%) developed an SPT, and 11 (20%) an LNM. Six of 55 
patients presented with multiple second locoregional neoplastic manifestations. One of 55 
patients (1.8%) developed a distant metastasis. Eleven of 55 patients (20%) died of OSCC; 
all presented with a locoregional neoplastic manifestation before death. The features of the 
study population in relation to DSS and LRC are summarized in Table 3. 
 Ki-67 values in the OSCC 
The Ki-67 values in the OSCC tumor mass ranged from 8% to 90% with a mean Ki67 value 
of 46.6 ± 22.3; 17 of 50 patients showed “low” Ki67 values and 33 showed “high” Ki67 
values in the tumor mass (>42%). 
Mucosal biopsies performed on the cheek opposite the OSCC: 
None of the biopsies presented features of squamous intraepithelial lesions (82). The Ki-67 
values in the clinically and histologically “non-neoplastic” mucosa distant from the primary 
OSCC ranged from 2% to 41% with a mean Ki67 value of 18.69 ± 9.1. Low Ki67 values 
(<20%) were observed in the 37 of 55 patients with “low” Ki67 values. Eleven patients with 
“low Ki67 values” (29.7%) presented with a second locoregional neoplastic event, of whom 
4 died of disease after a time interval ranging from 11 to 52 months (mean 25.5 ± 18.2 
months). High Ki67 values (>20%) and the presence of Ki67-positive mature keratinocytes 
were observed in 18 of 55 patients. Twelve patients (66.7%) with “high” Ki67 values (>20%) 
presented with a second locoregional neoplastic manifestation, of whom 7 died of disease 
after a time interval ranging from 1 to 66 months (mean 14.6 ± 23.1 months). Results of 
Kaplan Meier analysis showed that “high” Ki67values resulted in a variable significant 
association with worse LRC (χ2=10.6; p < .05). “High” Ki67 values also resulted in a variable 
significant association with worse DSS (χ2=6.5; p < .05) (Figs. 8 and 9). Histological grade 
also resulted in a variable significant relation with worse LRC (χ2= 6.02; p < .05) and DSS 
(χ2=16.8; p < .01); 3 of 5 patients (60%) with a poorly differentiated OSCC showed a second 
locoregional neoplastic manifestation, compared with 15 of 31 patients (48.4%) with a 
moderately differentiated OSCC and 5 of 19 (26.3%) with a diagnosis of well-differentiated 
OSCC. 
Three of 5 patients (60%) with a poorly differentiated OSCC died during follow-up (mean 5.6 
± 3.05 months; range 3e9 months), compared with 8 of 31 patients (48.4%) with a 
moderately differentiated OSCC (mean 23.37 ± 23.26 months; range 1e56 months). 
All patients with a diagnosis of well-differentiated OSCC survived during the follow-up period 
of the present study. 
Finally, Kaplan Meier analysis showed that LNM at presentation was related to lower 
survival in terms of LRC (χ2=3.8;p ¼ 0.04): 8 of 14 patients (57.1%) with LNM presented 
with a locoregional manifestation during follow-up, in comparison to 15 of 41 patients 
(36.6%) with N0 at presentation. N status was also related to worse DSS (χ2= 4.3; p ¼ 
0.03): 5 of 14 patients (35.7%) with a positive N value died during follow-up, in comparison 
to 6 of 41 patients (14.6%) with a negative N value at presentation. 
Predictivity of LRC by multivariate analysis using the Cox proportional hazards model 
showed that “high” Ki67 values in clinically and histologically normal distant mucosa were 
the most powerful prognostic factor (Table 4). Predictivity of DSS by multivariate analysis 
using the Cox proportional hazards model showed that histological grade was the most 
powerful prognostic factor (Table 5). 
Considering the group of 31 T1-2N0 OSCCs, univariate analysis demonstrated that the only 
variable statistically related to a worse LRC (χ2 =9.5; p < .01) and DSS ( χ2= 5.51; p < .05) 
was the presence of “high” Ki67 values in non-neoplastic distant mucosa : 7 of 11 patients 
(63.6%) with “high” Ki67 values (>20%) showed the appearance of a second locoregional 
event, in comparison to 4 of 20 (20%) patients with “low” Ki67 values (<20%). All 3 patients 
in the T1-2N0 group who died during follow-up showed “high” Ki67 values (>20%) (Figs. 10 
and 11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TAB.3 Univariate analysis for potential prognostic variables related to locoregional control and disease-specific survival. Entries in boldface and 
asterisk indicate statistically significant p values. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
FIG.8 Kaplan-Meier for disease free survival rate 
by Ki67 expression in the “normal” mucosa from 
the cheek opposite the OSCC. Significantly 
locoregional control( LCR p<0.01) was found for 
patients with high (>20%) Ki67 scores. 
FIG.9 Kaplan-Meier for disease free survival rate 
by Ki67 expression in the “normal” mucosa from 
the cheek opposite the OSCC. Significantly worse 
Disease Specific Survival ( DSS p<0.01) was found 
for patients with high (>20%) Ki67 scores. 
TAB4.Statistically significant variables by multivariate 
analysis for predicting locoregional control  
FIG.10  Kaplan-Meier for disease free survival rate 
by Ki67 expression in the “normal” mucosa from 
the cheek opposite the OSCC. Significantly 
locoregional control( LCR p<0.01) was found for 
T1-2N0 patients with high (>20%) Ki67 scores. 
FIG.11 Kaplan-Meier for disease free survival rate by 
Ki67 expression in the “normal” mucosa from the 
cheek opposite the OSCC. Significantly worse 
Disease Specific Survival ( DSS p<0.01) was found 
for T1-2N0  patients with high (>20%) Ki67 scores. 
  
 
 
 
 
 
 
 
DISCUSSION 
The poor survival of OSCC patients has traditionally been ascribed to the high rate of local 
recurrence (LR), second primary tumours (SPTs), and deaths due to comorbidity. Despite 
recent progress, accurate prediction of prognosis and choice of appropriate treatment has 
been hampered by the fact that even patients with a small tumor may have a fatal outcome 
(83,84) 
In 1953, Slaughter et al. proposed the “field cancerization” concept as a pathogenic 
pathway for the development of multiple primary OSCCs arising in different areas of the oral 
cavity, frequently associated with pre-neoplastic lesions. They postulated that OSCCs are 
often surrounded by genetically altered cells, and that SPTs can develop within this field as 
a result of independent events affecting multiple cells after continuous exposure to 
carcinogenic agents(5). Recent studies based on molecular techniques supported this 
hypothesis(69,74). Two previous studies proposed the analysis of Ki67 expression in areas 
distant from the original tumor as a prognostic marker, particularly in the clinically and 
histologically nonneoplastic mucosa located on the cheek opposite the primary OSCC 
(42,77). 
TAB5.Statistically significant variables by multivariate 
analysis for predicting Disease Specidfic Survival  
The Ki67 labelling index is a simple, low-cost procedure frequently used to assess cell 
epithelial turnover in the oral mucosa. Its role as a prognostic marker has been analyzed in 
several OSCC cohorts showing a good correlation between Ki67 expression in tumor mass 
and histological grading of OSCC(83,85–87). The authors of two studies proposed 
overexpression of Ki67 in the tumor mass as an independent prognostic marker(88,89) , 
although other studies did not find this relationship (90,91). 
In an article published in 2010, Gonzales-Moles et al. showed a good relationship between 
high Ki67 expression in non-tumor epithelium associated with OSCC and the risk of multiple 
tumours. They identified a significant difference in Ki67 expression in distant (>1 cm) and 
close (<1 cm) epithelium associated with OSCC in patients who experienced multiple 
tumours compared to controls and patients with single tumours(73). 
The results of both studies conducted in 2009 and 2011  showed that the Ki67 mean value 
in the oral mucosa distant from the primary mass was significantly higher than that in 
controls, and 20% of OSCC patients had an abnormally high cell turnover in the clinically 
and histologically non-neoplastic oral mucosa from the cheek opposite the primary tumor. 
Moreover, those data disclosed a relationship between abnormally proliferating areas and 
primary tumor aggressiveness in terms of locoregional recurrence. 
However, the limit of both studies was the short follow-up of patients, ranging from 1 to 49 
months, with approximately one third of patients followed up for less than 9 months. Instead, 
the OSCC cohort in the present study has a longer follow-up (mean 53.7 ± 32.4 months; 
range 12e110 months), and the role of Ki67 expression in clinically and histologically normal 
distant mucosa was analyzed in relation not only to LRC but also to disease-specific 
survival (DSS). 
The results showed a higher mean Ki67 value in patients who experienced a second 
neoplastic event and in patients who died of disease complications. High KI67 expression in 
distant mucosa together with tumor differentiation and LNM at presentation were all 
predictive variables for a worse prognosis in terms of LRC and DSS, but Ki67 expression 
was the most powerful independent prognostic factor related to LRC. Similar results were 
obtained considering only the group of T1-T2N0 OSCCs, emphasizing that Ki67 expression 
in distant mucosa is related to LRC and DSS even among early-stage OSCCs. 
These results confirm the findings of studies with shorter follow-ups and suggest that Ki67 in 
clinically and histologically “non-neoplastic” mucosa distant from the primary tumor could be 
a promising biomarker to better understand the biological nature of OSCC, including its 
aggressiveness and long-term survival rate. 
The long-term prognosis and choice of the most appropriate treatment in OSCC patients are 
routinely based on clinical and histological staging systems, such as histological grading or 
LNM(65,92,93) 
The present study confirmed the clinical value of these parameters as reliable prognostic 
markers, but they seem to lose their efficacy in predicting LRC and survival in early stage 
tumors, whereas Ki67 expression remains a reliable predictive marker also in this group of 
patients. The use of Ki67 in distant mucosa may be included in the list of clinical 
pathological biomarkers to be screened preoperatively, in surgical decision making, and as 
a good prognostic indicator of a more intensive surveillance during  follow up. 
In conclusion, although our data must be considered with caution due to the relatively small 
size of the cohort, the results of the present population study with a long-term follow-up 
period confirm the value of Ki67 expression in distant mucosa as a prognostic marker for 
OSCC patients.  
 
 
 
 
 
 
 
 
PROJECT 2 : INVESTIGATION OVER PROGNOSTIC VALUE OF mtDNA 
PHYLOGENETIC ANALYSIS AS A TOOL FOR CLONAL DIAGNOSIS OF SECONDARY 
EVENTS IN  ORAL SQUAMOUS CELL CARCINOMA( PUBBLISHED AS Clonal analysis as a 
prognostic factor in multiple oral squamous cell carcinoma.Oral Oncol. 2017 Apr;67:131-137) 
 
 
AIMS : 
 
A novel classification based on molecular methods to assess clonality defines three types of 
secondary oral squamous cell carcinoma (OSCC): second primary tumour (SPT) 
independent from the index tumour, local recurrence (LR), clonally related to the primary 
tumour, and second field tumour (SFT), derived from the same genetically altered mucosal 
field as the primary tumour. (49)The present study applied mtDNA analysis in a group of 
patients experiencing a second loco-regional neoplastic manifestation. 
The purpose was to differentiate secondary tumours into LRs, SPTs and SFTs and evaluate 
the prognostic impact in terms of survival rate. 
 
METHODS : 
The study population comprised 23 consecutive patients who experienced a second 
neoplastic loco-regional manifestation after complete surgical resection of a primary OSCC. 
The cohort included some patients analysed in previous reports (52,53), but a minimum 
follow-up of 24 months after the appearance of the second tumour was required for 
enrolment. The study was approved by the institutional ethical committee (mtDNA01, code 
020/2013/U/Tess), and informed consent was obtained from all patients. Twenty (86.9%) 
second neoplastic manifestations were OSCCs limited to the oral cavity whereas the 
remaining 3 (13.05%) presented a delayed lymph node metastasis (LNM) as a second 
event. Patients with LNM were enrolled only when the metastasis appeared 6 months or 
more after primary OSCC surgery. A surgical margin involved in the primary OSCC was 
considered an exclusion criterion.  
All 23 patients were treated at the Maxillofacial Surgery Unit of Bellaria Hospital, and at the 
Oral and Maxillofacial Surgery Unit of S. Orsola–Malpighi University Hospital during the 
period 2002– 2011. They all underwent surgical resection of OSCC in accordance with 
standard treatment practice(65). Surgery consisted of composite resections, including 
excision of the primary tumour with ipsilateral or bilateral neck dissection. Microvascular 
reconstruction was performed for patients with locally advanced stages. Post-operative 
radiation therapy was performed when indicated, depending on the tumour stage, surgical 
margins, node involvement, and extra-nodal spread, according to currently accepted 
criteria(78). Tissue samples of the primary tumour and second neoplastic manifestation 
were sent for histological analysis to the Sections of Anatomic Pathology of the University of 
Bologna at Bellaria Hospital and S. Orsola–Malpighi University Hospital. A sample of 
clinically healthy oral mucosa located on the cheek contralateral to the OSCC was collected 
from the study population during surgical resection of the index lesion and second tumours. 
Cells from clinically healthy mucosa were selected and served as control reference DNA for 
mtDNA analysis and/or to evaluate a potentially altered genetic field distant from the 
neoplastic lesion. All tissues were formalin-fixed and routinely paraffin-embedded (FFPE). 
From each block, sections stained with haematoxylin and eosin were obtained for routine 
diagnosis. Histological diagnoses were made following the criteria proposed in the World 
Health Organization Blue Book(94). The mucosal biopsy obtained from healthy mucosa was 
always evaluated histologically to exclude any oral potentially malignant lesions according 
to the Ljubljana system(82). 
 
Microdissection and DNA extraction 
Ten micrometer-thick sections were carefully microdissected for DNA extraction by means 
of the laser-assisted SLlcut Microtest (MMI GmbH, distributed by Nikon, 
http://www.mmimicro.com) as previously described(52,53) [14,15] to obtain homogeneous 
populations of tumour cells. Cells from normal mucosa were also selected for mtDNA 
analysis. DNA was purified using the Quick ExtractTM FFPE DNA extraction kit (Epicentre, 
Madison, WI, USA) following the manufacturer’s instructions. 
Mitochondrial DNA sequencing and analysis DNA was sequenced for mtDNA D-loop region 
and for TP53 by 454 platform (GSJunior, Roche, Branford, CT, USA). In brief, mtDNA D-
loop sequence analysis was performed by amplifying four segments, covering the whole 
region from position 15,995 to position 700, according to Anderson et al.(95) as described in 
the human mitochondrial database (NC_012920 gi:251831106, MITOMAP: a Human 
Mitochondrial Genome Database. Center for Molecular Medicine, Emory University, Atlanta, 
GA, USA, http://www.mitomap.org). Primers were designed using primer3 (http://www-
genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi) and their sequences have been 
reported(52,53). To generate amplicons for the 454 NGS library, fusion primers were 
designed to contain specific mtDNA primers, the A and B sequencing adapters and the key 
sequence required for 454 NGS, and one of 14 different10 bp multiplex identifier (MID) 
barcodes, according to the manufacturer’s GS FLX standard sequencing method. PCR 
reactions were performed in a 20 ll volume containing 5 pmol of each forward and reverse 
primer using Phusion II HotStart High Fidelity DNA Polymerase, following the instructions of 
the supplier (ThermoScientific, Pittsburg, PA, USA). PCR products were purified using the 
AmpPure kit (Agencourt, Beverly, MA, USA). The DNA sequence was analysed 
bidirectionally by the GSJunior sequencer (Roche, Branford, CT, USA) following the 
supplier’s recommendation with a threshold of at least 5% mutant reads using Amplicon 
Variant Analyzer software 2.7. Phylogenetic and cluster analyses were conducted using 
MEGA software version 5.2 (http://www.megasoftware.net) using the NJ method and 
Kimura-2 parameter with a Gamma model that corrects for multiple hits taking into account 
transitional and 
transversional substitution rates and differences in site substitution. Every NJ tree was 
tested for standard error by the bootstrap method as previously described(52,53). 
Statistical analysis 
Disease-specific survival was the outcome of interest in the present study. Patient age, 
gender, type of second neoplastic event (local event or LNM), localization of secondary 
OSCC, presence of a phylogenetic relationship between the index OSCC and the 
secondary tumour, genetic diagnosis of a second neoplastic event following the Braakhuis 
classification (LR, SPT or SFT) (49)were analysed for their relationship with outcome. 
Survival rate was estimated using the Kaplan-Meier method. Statistical significance was 
evaluated using the log rank test. Time was defined as the period between the appearance 
of the second neoplastic lesion and death of disease, or last follow-up visit. The statistical 
analysis also evaluated the potential influence of outcome variables related to index OSCC 
(T score of index OSCC, N score of index OSCC, tumour differentiation of index OSCC, 
localization of index OSCC). For this second analysis, time was defined as the period 
between the appearance of the primary neoplastic lesion and death of disease, or last 
follow-up visit. P values < 0.05 were considered statistically significant in all analyses. 
 
RESULTS: 
Study population: 
The study population comprised 16 women and 7 men aged 26–89 years with a mean age 
at second neoplastic event presentation of 63.65 ± 17.69. 
Genetic classification of secondary OSCCs in LR, SPT and SFT Secondary tumours were 
genetically categorized as LR, SPT and SFT following the Braakhuis et al. classification(49) 
on the basis of  the phylogenetic relationship between primary and secondary OSCC, and 
between the clinically and histologically normal mucosa distant from the index OSCC and 
the mucosa distant from the secondary OSCC. Based on mtDNA results, cases were 
classified as 
follows: 
  LR: when second manifestations were phylogenetically related to the index OSCC, and 
normal mucosa samples clustered together and were not genetically related to the index 
tumour or the recurrence. In our series seven second neoplastic events (30.4%) were 
phylogenetically related to the index OSCC. In all 7 cases the normal mucosa samples 
clustered together and were not genetically related to the index tumour or the recurrence 
(Fig. 12). On histology the LRs were not associated with epithelial precursor lesions (Fig. 
15a). 
  SPT: when second manifestations were phylogenetically independent to the index OSCC, 
and normal mucosa samples clustered together and were not genetically related to the 
index or secondary OSCC. Four cases were classified as SPT as they presented a clonal 
relationship between the normal mucosa located distant from the tumour, sampled at the 
time of the primary 
OSCC and the time of the second manifestation, whereas the two tumours were not clonally 
related, suggesting the occurrence of two genetically distinct neoplastic events (Fig. 13); 
  SFT: when second manifestations were phylogenetically independent to the index OSCC 
and normal mucosa samples did not cluster together but may be genetically related to the 
index tumour or the recurrence. In such cases the genetic distance in normal mucosa 
suggested presence an altered genetic field. Twelve patients showed no genetic 
relationship between the normal distant mucosa at the time of the primary OSCC and the 
normal distant mucosa at the time of the second manifestation, while both neoplastic events 
showed a clonal relation with the respective apparently normal mucosa. These features 
suggested a wide altered mucosal field, leading to a diagnosis of 
SFT (Fig. 14). 
  On histology SPT (Fig. 15b) and SFT (Fig. 15c) were associated with areas of high grade 
squamous intraepithelial lesions (HG SIL)(82,94). In SFT cases the areas of HG-SIL were 
multiple. 
The clinical and molecular profile of the second neoplastic event and related index OSCC 
are summarized in Table 6. 
Results from Kaplan-Meier statistics 
The log-rank test showed that the only independent prognostic factor related to a better 
survival rate (p < 0.05) was an altered mucosal field in non-clonal patients classifying the 
second neoplastic 
manifestation as SFT; only 2/12 (16.6%) SFT events failed, compared to 5/7 LRs (71.4%) 
and 3/4 SPTs (75%) (Fig. 16). Results from Kaplan-Meier statistics were summarized in 
Table 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
TAB 6. Clinical and molecular profile of the study population 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 12 Phylogenetic tree of a case interpreted as local recurrence (LR). The secondary tumour (OSCC2) resulted 
phylogenetically related to the index tumour (OSCC1) and the 
respective normal distant mucosa was phylogenetically related. 
FIG 13 Phylogenetic tree of a case interpreted as second primary tumour (SPT). The secondary tumour (OSCC2) resulted 
phylogenetically distant from the index tumour(OSCC1) and the respective normal distant mucosa was phylogenetically 
related. 
FIG 14  Phylogenetic tree of a case interpreted as second field tumour (SFT). The secondary tumour (OSCC2) resulted 
phylogenetically distant from the index tumour (OSCC1) and the respective normal distant mucosa did not show a 
phylogenetic relationship. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.15 Histology: (a) LR is characterized by the presence of neoplastic cells (arrow) in the muscular wall, not 
related with the epithelium. (b) SPT is associated with HG-SIL. 
The interface between non neoplastic oral epithelium and HG-SIL is indicated by the arrow. (c) SFT: the 
present case is a microinvasive OSCC (star). The surrounding mucosa 
presents an area of HG-SIL (empty arrow); normally looking oral epithelium (black arrow) is interposed 
between microinvasive OSCC and HG-SIL. 
Fig.16 Kaplan–Meier estimate for disease-free survival rate by genetic diagnosis of a second neoplastic event 
following the Braakhuis classification (LR, SPT or SFT). An altered mucosal field in non-clonal patients was 
the only prognostic factor related to a significantly better survival rate (p < 0.05). Indeed only 2/12 (16.6%) 
SFTs failed compared to 5/7 LRs (71.4%) and 3/4 SPTs (75%). 
  
 
 
 
 
 
 
DISCUSSION: 
mtDNA (D-loop) sequence analysis followed by NJ is a useful molecular method to assess 
tumour clonality [13–16,18–20]. In previous studies it was evaluated the reliability of mtDNA 
analysis in establishing the clonal relationship between paired neoplastic lesions in OSCC in 
comparison with the Hong classification based on clinical and histological criteria. Total 
agreement between mtDNA analysis and the Hong classification was found in 19/25 cases 
(76%). Specifically, complete agreement was achieved when mtDNA was compared with 
histopathological criteria, while discrepancies arose only in 6 cases in which the Hong 
classification was based only on the spatial or temporal distance of the second lesion(52). 
Subsequently it was evaluated the relationship between primary OSCC and lymph node 
metastasis in a series of patients with synchronous and metachronous metastases, 
comparing mtDNA results with those obtained by another clonality test, i.e. TP53 sequence 
analysis. The results of TP53 and mtDNA analysis were consistent, showing that all neck 
metastases clonally related to the index tumour also shared similar mutations in the same 
TP53 gene regions(53). Establishing a clonal relationship between a second neoplastic 
lesion and the index tumour is not simply a problem of classification but yields new insights 
into the patient’s tumour biology and can influence the prognosis and treatment of the 
second lesion. 
TAB 7.  Univariate analysis for Potential Prognostic Variables related to disease specific survival. Entry in 
boldface and with asterisk indicate statistically significant P values 
Few studies to date have analysed the difference in prognosis of patients with LR or SPT 
and SFT. Gonzalez Garcia et al. reported a lower survival rate in LR patients compared with 
patients with SPT(96) whereas Renmeno et al. found no differences in survival(97). 
However, the two studies used different clinical and histological criteria to differentiate LR 
from SPT: Gonzalez Garcia et al. used the Hong classification(98)  whereas Renmeno et al. 
used Warren and Gates’ criteria(48). To the best of our knowledge, this is the first study to 
analyse the prognosis of patients with multiple OSCCs following a classification based on 
molecular clonality assessment. The results revealed that the majority of second OSCC 
should be considered SFT, i.e. tumours phylogenetically independent from the primary and 
originating from a genetically altered mucosa. The present series found 12/23 SFT, 7/23 LR 
and 4/23 SPT. These results confirm the field cancerization theory that the mucosa 
surrounding the primary OSCC mass is characterized by genetically altered epithelial cells 
that can escape clinical and histologic examination and might be responsible for cancer 
progression. This concept is further supported by the presence of multiple HG-SIL areas 
observed in cases of SFTs. The presence of a genetically altered filed surrounding OSCC, 
originally proposed by Slaughter et al.(5), has been widely confirmed by biomolecular 
approaches during the last two decades(99). Recently, Dasgupta et al. identified 
mitochondrial DNA (mtDNA) mutations in histologically negative resection margins of 
OSCC(100), confirming that even clinically and histologically radical surgical excision can 
lead to genetically altered mucosa capable of further neoplastic transformation. Kaplan 
Meier analysis of our results showed that these second manifestations had a better 
prognosis (16% failures) than LRs (71% failures) or SPTs (75% failures). The worse 
prognosis of LRs with respect to SFTs in terms of survival is in accordance with the clinical 
data of Gonzalez Garcia et al.(96), while the higher failure rate of LRs is probably due to the 
difficulty of obtaining a radical excision of primary tumours when it is hard to identify 
microscopic disease remaining after surgery and adjuvant radiotherapy (101). In addition, 
the residual disease is often present as multiple neoplastic foci in cases of LR. Conversely, 
SFT could be considered a new tumour and is usually detected at an earlier stage due to 
active surveillance applied in patients treated for OSCC, thereby enhancing the prognosis. 
Unexpectedly, SPT showed an aggressive behaviour similar to LR, as 3/4 patients died of 
disease 3, 13 and 41 months respectively after the second neoplastic manifestation. In all 
three cases the second tumour appeared in the same area as the index OSCC and should 
have been classified as LR, following clinical and histological criteria. This observation 
suggests an interpretation bias. Primary OSCCs in these patients more likely developed 
subclones with a higher proliferation rate and aggressive molecular signature, accounting 
for the wide genetic distance between the primary OSCC and the second event. In these 
cases, the NJ trees displaying the mutational patterns of mtDNA should be considered only 
a snapshot of the tumour and do not differentiate them into LRs or SPTs. Additional 
genomic or epigenomic investigations could be needed to differentiate second events 
clonally related to primary OSCC (LRs) from clonally unrelated second manifestations in 
case of primary tumours containing multiple subclones. 
 
 
 
 
 
 
 
 
 
 
 
 
PROJECT 3 : STUDY OF INTRATUMOR HETEROGENEITY IN RECURRENT-
METASTATIC ORAL SQUAMOUS CELL CARCINOMA BY MEANS OF MULTI REGION 
NEXT GENERATION SEQUENCING AND mtDNA ANALYSIS( PUBBLISHED AS: Gabusi, A.; 
Gissi, D.B.; Tarsitano, A.; Asioli, S.; Marchetti, C.; Montebugnoli, L.; Foschini, M.P.; Morandi, L. Intratumoral 
Heterogeneity in Recurrent Metastatic Squamous Cell Carcinoma of the Oral Cavity: New Perspectives 
Afforded by Multiregion DNA Sequencing and mtDNA Analysis. J. Oral Maxillofac. Surg. 2019, 77, 440–455. 
 
 
AIMS:  
Improvements in sequencing technologies have revealed that genetic differences among 
neoplastic cells may reflect clonal expansion.(102) Intratumor heterogeneity (ITH) has been 
suggested to explain differences in prognosis and treatment response, indicating that 
personalized medicine is the goal of the future (103). Aim of this project was to study ITH in 
oral squamous cell carcinoma and to track tumour evolution from adjacent non neoplastic 
field to local neoplastic events developing after primary tumour. 
 
METHODS: 
Sample selection and DNA extraction  
ITH evolution was tracked using tissues representing selected stages in oral 
carcinogenesis. OSCC tends to relapse locally or to spread through lymphatic vessels. We 
obtained multiple samples from each tumor (tumor cell percentage >70%). The original 
histological slides were reviewed by two pathologists with experience in oral pathology, and 
areas ≥0.5 cm apart exhibiting different morphological features were selected for analysis.  
At least five 10-µm-thick sections of the same areas were macrodissected manually (using 
a scalpel) to collect about 1 cm2 tissue. The study was approved by our Institutional Ethics 
Committee (S. Orsola Hospital, project mtDNA01, approval code 020/2013/U/Tess) and 
informed consent was obtained from all patients. Additional samples were collected from 
diagnostic biopsies and mucosae surrounding tumors; again, all samples were ≥0.5 cm 
apart. Using the same protocol, multiple samples from surgical specimens of nodal 
metastases/secondary manifestations were collected and analyzed. DNA purification from 
each sample was performed as described previously(104). In brief, macrodissected tissue 
was digested at 56°C for 3 h using the solution of the Quick ExtractTM FFPE DNA 
extraction kit (Epicentre, Madison, WI, USA). After denaturation at 95°C for 5 min, each 
suspension was centrifuged at 10,000 x g at 4°C for 5 min to pellet undigested tissue and 
solidify floating paraffin. DNA for PCR was collected from the interphase and stored at 4°C.  
 
 
Next Generation Sequencing: 
We subjected the following genes (selected by DriverDBv2(105)) involved in head and neck 
squamous cell carcinogenesis(106) to deep sequencing: KRAS (exons 2–4), NRAS (exons 
2–4), HRAS (exons 2, 3), BRAF (exon 15), PIK3CA (exons 10, 21), TP53 (exons 4–9), 
NOTCH1 (exons 4, 6, 11, 26, 27), PTEN (exons 5–8), CDKN2A (exons 1, 2), EGFR (exons 
18–21), AKT1 (exon 2), and CTNNB1 (exon 3). Locus-specific amplicon libraries with 
tagged primers were generated using overhang adapters based on the 5′ Nextera 
sequences; these were recognized during the second round of short PCR, which added 
P5/P7 sequencing adapters (Illumina, San Diego, CA, USA) and sample-specific indices. In 
the first round of enrichment PCR, seven multiplex PCR tubes were used for parallel 
amplification of all the above DNA regions using Phusion U (Thermo Fisher, Waltham, MA, 
USA) as the proofreading enzyme. The amplification products were mixed and purified 
using MagSi-NGSPREP-Plus beads (Magnamedics, Geleen, the Netherlands), quantified 
with the aid of a Quantus fluorometer (Promega, Madison, WI, USA), and employed as 
templates (100 ng) in the second (barcoding) PCR step (eight cycles). The amplicons were 
purified using MagSi-NGSPREP beads, quantified employing the fluorometer, pooled, and 
loaded onto a MiSEQ platform (Illumina). FASTQ files trimmed in terms of the multiplex 
identifiers were used for quality control.  Only reads of PHRED quality score > Q30 and 
length > 100 bp were retained for mapping and variant analysis in a Galaxy Project 
environment(107). Raw reads were mapped to the hg19 human reference genome 
sequence, and read alignment files in BAM format were generated with Bowtie2 mapping, 
GATK local realignment, HaplotypeCaller and Picard MarkDuplicates. The BAM files were 
analyzed using an Integrative Genomic Viewer (IGV)(108) to manually identify all mutations 
of a clinical sensitivity threshold > 2%; only bidirectional variant calls with more than 10 
reads were reported(109). The depth of coverage was assessed manually using the IGV, 
and regions with less than 100 reads were discarded. To test the reliability of variant allele 
frequencies (VAFs), three cell lines with known mutations (SW620: KRAS pG12V; CAL62: 
KRAS p.G12R; OCUT: BRAF p.V600E) were spiked into a background of wild-type DNA 
(DNA female pool, code G1521; Promega) at different concentrations, as described 
previously(110). ASLNAqPCR (an orthogonal method) was used to derive sensitivities and 
specificities for detection of KRAS codons 12–13 and BRAF codon 600(110)(111). 
 
 
 
Phylogenetic trees 
Phylogenetic trees were constructed as described previously(112)(113)(114), with some 
modifications. D-loop sequencing featured amplification of four segments covering the 
region from positions 15,995 to 700 of human mitochondrial DNA (NC_012920 
gi:251831106; MITOMAP: a Human Mitochondrial Genome Database, 
http://www.mitomap.org). Locus-specific amplicon libraries with tagged primers were 
generated using overhang adapters based on the 5′ Nextera sequences, as described 
above for OSCC driver genes. FASTQ files were filtered in terms of PHRED score > Q30 
and read length > 100 bp, as above, and converted to FASTA format. Four FASTA files 
representative of each of the four D-loop fragments were created by Perl and processed by 
Geneious 9.1.8 (Biomatters Ltd., Auckland, New Zealand) to allow for multiple sequence 
alignment to identify heteroplasmies. The four consensus sequences were then joined and 
used to construct  phylogenetic trees employing MAFFT 
(https://mafft.cbrc.jp/alignment/server/), with UPGMA/Jukes-Cantor serving as the substitute 
model(115). 
 
Evaluation of tumor heterogeneity 
The ITH of OSCC somatic mutations was derived by calculating the heterogeneity rates of 
all affected genes and dividing that sum by the number of affected genes not shared by all 
tumor regions, as described previously(116). These values were used to compare the ITH 
of nodal metastases and secondary events (assessed independently). ITH was also 
calculated for non-neoplastic mucosae surrounding primary tumors, to explore field 
cancerization. 
  
RESULTS 
Patient characteristics 
Three of the five patients were male; the median age of all patients was 59.6 (SD, 5.5) 
years; all were non-smokers. All primary tumors arose in the oral cavity; four were in the 
tongue (patients 1, 3, 4, and 5) and one arose on the floor of the mouth (patient 2). In terms 
of the pTNM classification(79), patient 1 was pT3N2cM0; the others exhibited no nodal 
involvement at diagnosis and were classified as pT2N0M0, pT4N0M0, pT1N0M0, and 
pT2N0M0, respectively (Table 1). All patients underwent radical surgery with clear margins. 
No intraepithelial precursor lesion was detected histologically on the resection margins.  
During post-surgical follow-up, patients 1, 4, and 5 did not relapse. Patients 2 and 3 
developed several neoplastic lesions at different oral cavity sites, including sites distant from 
the primary tumors. Patient 2 developed five additional tumors and patient 3 developed two. 
 
ITH of the primary tumors: 
The mutational profiles were used to compare the primary tumors. Although TP53 was 
mutated in many tumors, the mutations differed. Only two PIK3CA mutations were found in 
more than one patient (PIK3CA p.W1051* in patients 3 and 4; PIK3CA p.G1050S in patients 
3 and 5). 
 
ITH of nodal metastases and subsequent neoplastic events: 
We compared the genetic profiles of metastases and secondary events with those of the 
primary tumors. In patient 1 (pT3N2cM0), almost all mutations in the primary tumor, except 
for BRAF p.T599K, endured during nodal invasion. However, in patient 2, the primary tumor 
and the later neoplastic event did not share any mutation. Specifically, although the KRAS, 
TP53, and NOTCH1 genes were mutated in both samples, the loci differed. However, the 
KRAS mutation acquired by the second carcinoma (KRAS p.A130Q) persisted in the third to 
sixth neoplasias. In patient 3, the primary tumor and the second event did not share 
mutations, and the mutations in the third carcinoma were unique to that event. 
 
ITH of primary tumors 
The ITH of all primary tumors was analyzed by comparing different tumor regions. Four 
samples from patient 1 were analyzed (Table 2). Only four of nine mutations were shared by 
all samples (5/9 not shared, heterogeneity rate [HR] = 55%). Notably, the BRAF p.T599K 
mutation was evident in only one of the four samples; for CTNNB1, multiple mutations 
(p.A43S, p.V57G) were present in the same samples (2 and 3), but only one mutation 
(p.V57G) was found in both samples 1 and 3. In patient 2 (Table 3), 10 mutations were 
found, but none were shared (HR 100%). Although TP53, CDKN2A, and PTEN were 
mutated in all samples, all mutations were unique. KRAS was mutated in one sample only, 
as was BRAF (p.V600M in sample 3). In patient 3 (Table 4), three samples contained a total 
of seven mutations; none were shared (HR 100%). NOTCH1 was mutated in all three 
samples, but the mutations were unique. KRAS and TP53 were mutated in one sample (#1), 
but not in the others. PIK3CA was not mutated in sample #1, but was mutated at different 
loci in the other two samples (p.G1050S and p.G1051*, respectively). Of five samples from 
patient 4 analyzed, one (# 5) did not amplify correctly. Six mutations were identified; all were 
unique (HR 100%). Four samples from patient 5 contained six mutations; all were unique 
(HR 100%). 
 
ITH of non-neoplastic mucosae and nodal metastases/subsequent neoplastic events 
For patient 1, we analyzed two samples from the adjacent non-neoplastic mucosa. All 
mutations were shared by the primary tumor and the mucosa. The two samples differed 
only in the absence of the TP53_C>T splicing mutation from sample #1 (HR 14%). We 
analyzed four samples from the nodal metastasis, but DNA amplification failed for sample 
#3. Four of eight mutations were not shared (HR 37%). We analyzed two non-neoplastic 
mucosal samples from patient 2; six unique mutations were found (HR 100%). The ITH of 
four of the five recurrences was studied (one of two samples from the third recurrence did 
not amplify). The second carcinoma had four mutations (two samples). KRAS (p.A130Q) 
was present in both samples, but mutations in TP53, PTEN, and NOTCH1 were identified in 
only one sample. In the fourth neoplasm, the same KRAS mutation (KRAS p.A130Q) was 
present in both samples analyzed. Additional mutations were found in NOTCH1 of only one 
sample (HR 50%). In the fifth and sixth carcinomas, KRAS_p.A130Q remained present in all 
samples; this was the only mutation found in the sixth carcinoma. The HRAS (p.G13D) 
mutation was shared by all samples from the fifth recurrence. Mutations were also found in 
TP53, CDKN2A, PTEN, and NOTCH1, but (apart from NOTCH1; both samples mutated, but 
in different loci), the mutations were present in only one sample (HR 71% and 0% for fifth 
and sixth recurrences, respectively). 
 
The non-neoplastic mucosal samples from patient 3 could not be amplified. Patient 3 
developed two additional carcinomas with HRs of 100%. Patient 4 yielded only one sample 
of non-neoplastic adjacent mucosa, in which mutations were found. Patient 5 yielded three 
samples from non-neoplastic adjacent mucosa; only one sample harbored a mutation (TP53 
p.L194F; HR 100%). 
 
Phylogenetic analysis of mtDNA 
D-loop mtDNA analysis was used to integrate the genetic relationships of the multiple 
samples from different tumor regions(114),(113),(112),(104).. For patient 1, clusters of 
primary 2 with nodal metastases 1, 3, and 4, and of primaries 3 and 4 with nodal metastasis 
2 and normal epithelium are shown in Figure 3A. Primary 1 was completely independent. 
The short secondary branches of the phylogenetic tree indicate that the genetic 
relationships were close. Patients 2 and 3 yielded different patterns; nodal metastasis did 
not occur, but local recurrences were analyzed. In patient 2 (Fig. 3B), the samples from 
non-neoplastic mucosa were (closely) phylogenetically related to the primary tumor. 
However, although primary tumor samples 1 and 2 were phylogenetically related to each 
other and to non-neoplastic mucosa, sample 3 belonged to a distinct evolutionary line. 
Analysis revealed long secondary branches indicating wide genetic distances. A similar 
pattern was evident in patient 3 (Fig. 3C). Patients 4 (Fig. 3D) and 5 (Fig. 3E) did not 
develop neoplastic events after removal of the primary tumors. In both patients, mtDNA 
analysis disclosed the presence of at least two clusters within the tumors and different 
phylogenetic distances between multiple samples from the tumors and the non-neoplastic 
adjacent mucosae.       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 17. Hematoxylyn and Eosin  of primary tumour 
from patient 1 with related multiple tumor regions. 
FIG 18. Hematoxylyn and Eosin  of lymph node 
metastasis from patient 1 with related multiple tumor 
regions. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8:Summary of patient characteristics: (M: Male F: Female) 
 
Table 9: mutational profile of patient 1 considering the various events (VAF: variant allele frequency; NA: not avaliable) and heterogeneity rate; 
DOC: depth of coverage: 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 10 : mutational profile of patient 2 considering the various events and heterogeneity rate (VAF: variant allele frequency; NA: 
not avaliable; DOC: depth of coverage): 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 11 : mutational profile of patient 3 considering the various events and heterogeneity rate (VAF: variant allele 
frequency; NA: not avaliable; DOC: depth of coverage): 
 
Table 12: mutational profile of patient 4 considering the various events and heterogeneity rate (VAF: variant 
allele frequency; NA: not avaliable; DOC: depth of coverage): 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 19: Phylogenetic trees by sequencing of mtDNA D-loop region using UPGMA: 
A: primary 2 clusters with nodal metastases 1, 3, and 4, primaries 3 and 4 with nodal metastasis 2 and normal epithelium. 
Primary 1 was completely independent. The short secondary branches of the phylogenetic tree indicate that the genetic 
relationships were close. 
B: Phylogenetic tree of patient 2: the samples from non-neoplastic mucosa were closely phylogenetically related to the 
primary tumor. Primary tumor samples 1 and 2 were phylogenetically related to each other and to non-neoplastic mucosa, 
sample 3 belonged to a distinct evolutionary line. Analysis revealed long secondary branches indicating wide genetic 
distances. 
C: Phylogenetic tree of patient 3: primary 1 and 3 were closely related to second 1. The other elements of the tree were less 
related each other. 
D: Phylogenetic tree of patient 4: all collected primary tumors, except primary 2, were genetically identical. 
E: Phylogenetic tree of patient 5: primary 1, 2, 3 clustered together, while primary 4 took place independently.  
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Table 13: mutational profile of patient 5 considering the various events and heterogeneity rate (VAF: variant 
allele frequency; NA: not avaliable; DOC: depth of coverage): 
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Discussion 
OSCC is a locally aggressive tumor of epithelial origin. Despite multimodal treatment 
(surgery, radiation, and/or chemotherapy), most patients develop multiple local relapses or 
distant metastases(117). Many cases are diagnosed at advanced stages, which may render 
prognosis unfavorable(118). Although early diagnosis has improved, neither overall survival 
nor long-term prognosis has changed significantly in recent years(119). The Slaughter 
theory of field cancerization explains the development of recurrence(69),(120),(121). Many 
molecular studies have confirmed genetic abnormalities in regions distant from primary 
OSCCs, even in the absence of histological or clinical changes(122),(123). Many efforts 
have been made to identify histological or molecular biomarkers predicting relapse or 
treatment failure. However, neither the use of biomarkers nor modern drugs (i.e., 
cetuximab) has improved overall survival or locoregional control(124). ITH may explain the 
observed variations in clinical behavior and responses to treatment; subcloning may foster 
tumor aggressiveness(125).  
 
In other anatomical areas, genetic analysis of various tumor regions revealed ITH(126). 
NGS permits parallel in-depth investigation of genomic hot spots, with work at the single-cell 
level. Unlike Sanger sequencing or allele-specific qPCR, deep parallel NGS allows 
quantitative investigation of several genomic targets in a single experiment, commencing 
with FFPE tissue. Our patients exhibited unique genetic patterns. Although genes such as 
TP53 were mutated in all five patients, the mutations were identical in only two cases 
E 
(PIK3CA p.W1051* in patients 3 and 4; PIK3CA p.G1050S in patients 3 and 5), confirming 
high-level heterogeneity among tumors of the same subtype, similar to other studies(127),; 
individualized molecular diagnosis is essential.  
 
Our ITH data confirm that analysis of a single tumor sample underestimates the mutational 
landscape. As several subclones co-existed in our patients, mutations were evident in a few 
tumor regions (i.e., the PTEN mutations of patient 4 differed in samples 1–3 of the primary 
tumor). We evaluated ITH quantitatively by calculating HRs(116), which ranged from 55% to 
100%. In patient 1 (HR 55%), half of the mutations were not shared by all tumor regions. In 
patients 2 and 3 (HR 100%), no mutation was shared by all samples. Thus, clinical 
information from a single biopsy should not be used to drive clinical decisions or reach 
biological conclusions.  
 
Several attempts have been made to quantify intratumor heterogeneity. Mroz et al. 
developed a system (MATH)(127) for the scoring of dispersion of mutant allele frequencies 
from single WES samples. Despite the absence of data from multiple samples, high-level 
heterogeneity was associated significantly with poor prognoses and treatment 
responses(128). We found that the ITH of early-stage and advanced tumors was high. High 
ITH rates were evident even in the tumors of patients who were free of neoplastic events 
during post-surgical follow-up, as well as in patients with less favorable clinical courses. 
However, the prognostic implications of our analysis should be tested in a larger patient 
population. 
  
Multiregion tumor sampling yields useful clinical and prognostic information in terms of 
individualized diagnoses and can be used to track tumor evolution. Mutations present at one 
stage of tumor evolution may later be lost. For example, BRAF mutations were found only in 
single samples of the primary tumors of patients 1 and 2, and were subsequently lost, 
perhaps because the mutations did not afford a proliferative advantage. However, certain 
mutations persisted during tumor evolution. Interestingly, in patient 2, the second OSCC 
acquired a KRAS mutation retained in all subsequent relapses by all samples; a dominant 
subclone controlled tumor evolution. Patient 3 exhibited extreme heterogeneity; early 
subclones were replaced by new subclones, reflecting genetic instability(129). Overall, ITH 
analyses of primary tumors and subsequent neoplastic events revealed different patterns of 
disease evolution, enriching our understanding of OSCC biology and informing future 
treatment strategies. 
 
Previous studies have used mtDNA analysis to distinguish second primary tumors from 
local recurrences(130)(104)(114)(113). mtDNA is more abundant than nuclear DNA, 
overcoming amplification failure from formalin-fixed paraffin-embedded tissues that may 
have been over-fixed or contain little DNA. Moreover, mtDNA is non-coding and generally 
accumulates neutral mutations; mtDNA does not influence cell proliferation. For patient 1, 
sample 3 of the nodal metastasis lacked adequate DNA for analysis, but phylogenetic 
relationships could be derived based on mtDNA. In this case, the primary tumor and the 
metastases were closely related (Fig. 3A), in agreement with the low level of tumor 
heterogeneity evident on driver gene analysis. This is also in accordance to a particular 
study by Wen B. et al whose conclusions state that genetically clonal tumor cells are 
predominantly responsible for the composition of metastatic primary tumors and their paired 
lymph node metastases(133). In contrast, the phylogenetic trees of patients 2, 3, and 5 
revealed that tumor evolution was accompanied by high-level heterogeneity; the between-
sample genetic distances were large, as evidenced by the lengths of the secondary 
branches. However, patient 4 expressed four closely related subclones (primaries 1, 3, 4, 
and 5) and only one independent subclone (primary 2). 
 
Non-neoplastic mucosal analysis in terms of driver genes and mtDNA indicated that field 
cancerization was present in almost all cases. In patient 1, many mutations were common 
to the non-neoplastic surrounding mucosa and the primary tumor. In patients 2 and 5, 
different mutational patterns were evident in adjacent, morphologically normal tissue; all 
genes evaluated from patient 4 were wild type. Thus, from a phylogenetic viewpoint, case 2 
showed that normal mucosa could cluster with different tumor subclones, indicating the 
presence of a “second field tumor,” first described by Braakhuis et al.(131) and confirmed by 
Gissi et al.(104) This tumor arises from the same genetically altered mucosal field as the 
primary OSCC, but the tumors share only some (not all) genetic alterations. Interestingly, 
some heterogeneity was also evident among multiple samples of non-neoplastic mucosa; 
this constitutes the first evidence of intrafield heterogeneity. A heterogeneous pre-neoplastic 
field may affect prognosis and treatment. Indeed, different tumor areas may vary in terms of 
aggressiveness, requiring different surgical approaches and adjuvant or neoadjuvant 
treatment. 
In conclusion, even though the sample size is very small and heterogeneous with regard to 
anatomic site, our study of tumor heterogeneity revealed a complex OSCC landscape. This 
report may be considered a proof of principle which demonstrates that genetic analysis of 
tumors is important to develop a mutational profile of disease, which differs for every 
patient. Molecular study of a single biopsy does not yield information that is representative 
of the disease or useful when planning individualized surgical or medical therapy. 
Multiregion tumor analysis detects clonal mutations that persist during tumor evolution. 
Molecular heterogeneity involves not only the primary tumor and local recurrences, but also 
the surrounding field. The surgical implications of this fact remain to be explored. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
PROJECT 4: INVESTIGATION OVER INTRATUMOR  HETEROGENEITY AS A 
PROGNOSTIC FACTOR IN PREDICTING DISEASE RELAPSE IN ORAL SQUAMOUS 
CELL CARCINOMA 
AIMS:  
Limited clinical value of a single sample for the assessment of molecular profiles of tumours 
is a direct consequence of intratumour heterogeneity (ITH).(132) Therapeutic strategies 
based on lacking molecular diagnosis expose clinicians to the risk of errors and distortions. 
Therefore, the study of intratumor heterogeneity is the goal of future precision medicine. 
Prognostic implications of intratumour heterogeneity are not fully understood.  Aim of this 
project was to investigate the relationship between ITH and local progression of OSCC.  
METHODS: 
Patients selection: 
Patients operated for OSCC and attending regular follow up for disease relapse at the Unit 
of  Oral Medicine and  Maxillofacial Surgery S.Orsola Hospital, University of Bologna were 
recruited for the study.  
Inclusion criteria:  
- A diagnosis of primary tumor  of T2-T4 according to the p-TNM classification of 
tumours(Amin MB, Edge SB, Greene FL, et al, eds. AJCC Cancer Staging Manual. 
8th ed. New York: Springer; 2017). 
- Absence of Nodal involvement 
- Absence of lichenoid inflammation in tumour microenvironment 
- Surgical margin of resection free from neoplasia 
- Follow up ≥ 3 years after surgical resection 
If during the follow up interval the patient had experienced disease progression, he/she was 
included in group 1 (recurrent OSCCs), otherwise, if no relapses were recorded, the patient 
was included in group 2 (non-recurrent OSCCs). Recruitments of both cohorts ended when 
numerosity reached the 5 units for a total of 10 studied patients.   
Selection of the sampled areas: 
Multiple samples were obtained from each tumour and from related adjacent non neoplastic 
mucosa. In particular, with respect to primary tumours, histological slides were reviewed 
with the help of expert pathologists and two areas ≥0.5 cm apart exhibiting 70% of tumor 
cells were selected for analysis. At least five 10-µm-thick sections of the same areas were 
macrodissected manually (using a scalpel) to collect about 1 cm2 tissue. The study was 
approved by our Institutional Ethics Committee (S. Orsola Hospital, project mtDNA01, 
approval code 020/2013/U/Tess) and informed consent was obtained from all patients. Two 
additional samples were collected from mucosae surrounding tumors; again, all samples 
were ≥0.5 cm apart. Using the same protocol, two samples from surgical specimens of 
secondary manifestations were collected and analyzed. DNA purification from each sample 
was performed as described in project 3. In brief, macrodissected tissue was digested at 
56°C for 3 h using the solution of the Quick ExtractTM FFPE DNA extraction kit (Epicentre, 
Madison, WI, USA). After denaturation at 95°C for 5 min, each suspension was centrifuged 
at 10,000 x g at 4°C for 5 min to pellet undigested tissue and solidify floating paraffin. DNA 
for PCR was collected from the interphase and stored at 4°C.  
Next Generation Sequencing 
We subjected the following genes (selected by DriverDBv2(105)) involved in head and neck 
squamous cell carcinogenesis(106) to deep sequencing: KRAS (exons 2–4), NRAS (exons 
2–4), HRAS (exons 2, 3), BRAF (exon 15), PIK3CA (exons 10, 21), TP53 (exons 4–9), 
NOTCH1 (exons 4, 6, 11, 26, 27), PTEN (exons 5–8), CDKN2A (exons 1, 2), EGFR (exons 
18–21). Locus-specific amplicon libraries with tagged primers were generated using 
overhang adapters based on the 5′ Nextera sequences; these were recognized during the 
second round of short PCR, which added P5/P7 sequencing adapters (Illumina, San Diego, 
CA, USA) and sample-specific indices. In the first round of enrichment PCR, seven 
multiplex PCR tubes were used for parallel amplification of all of the above DNA regions 
using Phusion U (Thermo Fisher, Waltham, MA, USA) as the proofreading enzyme. The 
amplification products were mixed and purified using MagSi-NGSPREP-Plus beads 
(Magnamedics, Geleen, the Netherlands), quantified with the aid of a Quantus fluorometer 
(Promega, Madison, WI, USA), and employed as templates (100 ng) in the second 
(barcoding) PCR step (eight cycles). The amplicons were purified using MagSi-NGSPREP 
beads, quantified employing the fluorometer, pooled, and loaded onto a MiSEQ platform 
(Illumina). FASTQ files trimmed in terms of the multiplex identifiers were used for quality 
control.  Only reads of PHRED quality score > Q30 and length > 100 bp were retained for 
mapping and variant analysis in a Galaxy Project environment(107). Raw reads were 
mapped to the hg19 human reference genome sequence, and read alignment files in BAM 
format were generated with Bowtie2 mapping, GATK local realignment, HaplotypeCaller 
and Picard MarkDuplicates. The BAM files were analyzed using an Integrative Genomic 
Viewer (IGV)(108) to manually identify all mutations of a clinical sensitivity threshold > 5%; 
only bidirectional variant calls with more than 10 reads were reported(109). The depth of 
coverage was assessed manually using the IGV, and regions with less than 100 reads were 
discarded. To test the reliability of variant allele frequencies (VAFs), three cell lines with 
known mutations (SW620: KRAS pG12V; CAL62: KRAS p.G12R; OCUT: BRAF p.V600E) 
were spiked into a background of wild-type DNA (DNA female pool, code G1521; Promega) 
at different concentrations, as described previously(110). ASLNAqPCR (an orthogonal 
method) was used to derive sensitivities and specificities for detection of KRAS codons 12–
13 and BRAF codon 600(110)(111). 
  
Evaluation of intratumor heterogeneity (ITH) 
The reliability of a single sample to reflect the genetic profile of the tumor was assessed in 
both groups comparing the number of somatic mutations obtained from one sample with 
respect to  multiple samples investigation.   
Similarly, the occurrence of a WT/Mutated dicrepancy among samples was analyzed to 
investigate the implications of a targeted therapy guided by a single tumor sample. In 
particular if one sample exhibited mutations in a studied gene but the other was wild type 
patient was considered discrepant. On the contrary, if both samples were mutated or both 
wild type no discrepancies were recorded. 
The degree of ITH for OSCC somatic mutations was derived by calculating the 
heterogeneity rates (HR)  of all affected genes and dividing that sum by the number of 
affected genes not shared by all tumor regions, as described previously(116). These values 
were used to compare the ITH in the group of recurrent and non recurrent OSCCs. The 
same protocol was used in the group of recurrent OSCCs for secondary neoplastic events 
to compare ITH values during tumour evolution. ITH was also calculated in both groups for 
non-neoplastic mucosae surrounding primary tumors, to explore field cancerization.  
 
Tracking Tumor Evolution: 
OSCC genetic profiles obtained from multiple samples were used to identify mutations that 
persisted during tumor evolution and in particular from adjacent non neoplastic filed. 
In addition, the investigation of genetic relationship among samples was enriched by mtDNA 
analysis. Phylogenetic trees were constructed as in project 3. D-loop sequencing featured 
amplification of four segments covering the region from positions 15,995 to 700 of human 
mitochondrial DNA (NC_012920 gi:251831106; MITOMAP: a Human Mitochondrial 
Genome Database, http://www.mitomap.org). Locus-specific amplicon libraries with tagged 
primers were generated using overhang adapters based on the 5′ Nextera sequences, as 
described above for OSCC driver genes. FASTQ files were filtered in terms of PHRED 
score > Q30 and read length > 100 bp, as above, and converted to FASTA format. Four 
FASTA files representative of each of the four D-loop fragments were created by Perl and 
processed by Geneious 9.1.8 (Biomatters Ltd., Auckland, New Zealand) to allow for multiple 
sequence alignment to identify heteroplasmies. The four consensus sequences were then 
joined and used to construct  phylogenetic trees employing MAFFT 
(https://mafft.cbrc.jp/alignment/server/), with UPGMA/Jukes-Cantor serving as the substitute 
model(51). 
 
 
 
RESULTS: 
 
Patients Characteristics: 
In the group of 5 Recurrent OSCC 2 patients were female and 3 patients were female ( 
mean age 53±12,9 ). In the group of 5 non recurrent OSCC 4 patients were male and 1 
patient was female (mean age 53±9.2). Affected areas in the group of recurrent OSCC 
included (cheek, gingiva, tongue, floor of the mouth) whereas in the group of non-recurrent 
OSCCs arose in tongue and gingiva. 
All ten tumours exhibited histological evidence of submucosal infiltration. The degree of 
differentiation in the group of recurrent OSCCs  was 2/5 well differentiated, 2/5 moderately 
differentiated and 1/5 scarcely differentiated. In the group of non-recurrent OSCCs 2/5 were 
moderately differentiated and 3/5 well differentiated. 
In the group of recurrent OSCC 3/5 developed 2 more neoplastic events after surgical 
excision, 1/5 one subsequent event and 1/5 5 neoplastic events following primary tumor. 
  
Mutational Analysis: 
We investigated the effect of Intratumoral heterogeneity on the representativeness of  single 
samples comparing the number of mutations found in the tumour whether one or more 
samples were analysed.  
In primary tumours of  both groups of OSCC  9 out of 10 (90%)  single samples yielded a 
number of somatic mutations which was lower than the number of mutations derived from 
multiple samples analysis.(Fig.20A) 
In non neoplastic adjacent mucosae, mutational analysis based on a single sample was less 
informative than the multi samples approach in 7 out of 8 cases in the group of recurrent 
OSCC (samples from patient 5 couldn’t be amplified). (Fig.20C) By contrast,  only 3 out of 
10 samples from the group of non recurrent OSCC were less informative than the 
combination of two samples for the analysis of  mutational profile of the tumour surrounding 
field. 
In recurrent local events,8  out of 10 (80%) single samples from the second event yielded a 
number of somatic mutations which was inferior to multiple samples analysis whereas the 
same trend was observed in 4 out of 6 samples from the third event developed after primary 
tumour. Only one patients developed further events. (Fig.20B) 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG.20 The figure illustrates the reliability of a single sample in describing mutational profile in primary 
tumors (A), secondary adverse events (B) and adjacent mucosa (C). Green columns refer to samples in 
which the number of DNA somatic mutations in the ten studied genes were quantitatively   inferior to  the 
number of mutations derived from multiple samples analysis. Conversely, Blue columns refer to samples 
in which the  number of  somatic mutations was  superimposable to  somatic  mutations calculated with 
multiple samples.  
A B 
C 
  
The occurrence of a WT/Mutated discrepancy among samples was analysed in all OSCC 
cases and for all 10 studied genes, to investigate one of major risks of molecular 
misdiagnosis that may lead to inappropriate targeted therapies : KRAS (2/10) NRAS(3/10) 
HRAS(3/10) BRAF(1/10) EGFR(2/10) TP53(4/10) CDKN2A(3/10) PTEN(1/10) 
NOTCH1(3/10) PIK3CA(1/10).(Table 14) 
 
 
 
 
 
 
 
 
 
 
 
 
Values of Heterogeneity Rate (HR) in primary tumours and adjacent mucosa:  
 
The degree of ITH for studied primary OSCCs was derived by calculating the heterogeneity 
rates (HR)  of all affected genes and dividing that sum by the number of affected genes not 
shared by all tumor regions.(116) 
HR values between groups were then statistically compared using the non parametric U-
Mann-Whitney test for independent samples (IBM® SPSS Software v.21). P value scored 
Table 14 The occurrence of WT/Mutated discrepancy  between samples may reflect  a source of bias for  targeted molecular therapy. 
1= presence of discrepancy. One out of 2 samples harbored genetic mutations in a studied genes while the other sample from a 
distant area resulted wild type (WT). 0= absence of discrepancy. Both samples mutated or both WT 
0,095 and did not reach significance indicating the absence of a statistical  difference in the 
degree of intratumor heterogeneity among the groups of recurrent and non recurrent OSCC. 
By contrast,  U-Mann-Whitney test performed on samples from non neoplastic adjacent 
mucosa disclosed that non recurrent OSCC tends to exhibit statistically lower values of HR 
if compared to recurrent OSCCs ( p= 0,032). 
A statistical relation was also investigated between HR and clinical site among the ten 
studied tumours. Sites were divided in two groups; one involving tongue and  the other 
comprising sites other than tongue. No statistically significant relations were found 
(p=0,114).(Table 16-17-18) 
 
Values of Heterogeneity Rate (HR) and local progression of the disease: 
HR was calculated also for neoplastic events following primary tumour. Among second 
events, 3 out 5 cases exhibited HR values that were lower/equal if compared to related 
primary tumour. None of the three events developed after second tumour had HR values 
that were greater than its corresponding predecessors. Only one patient developed several 
events following the third. In particular, fourth and third events had superimposable values 
of HR, fifth event had HR values greater than its predecessor while in sixth event HR was 
lower than in the fifth. More in general, if secondary neoplastic manifestations were 
analysed together, 8 out of 11 cases exhibited HR values that were lower/equal if compared 
to the previous event.(Table 19) 
 
Analysis of tumor evolution through mutational analysis: 
Somatic mutations derived from multi samples analysis of tumours were analyzed during 
disease progression. In particular, we found 9 mutations that showed the ability to be 
transferred  to future adverse events. Mutations involved the genes  KRAS(p.A130Q) 
NRAS(p.G138R) HRAS(p.H27H) EGFR(p.Q787Q and p.R836R) TP53(p.Y236* and 
p.R273C) NOTCH1( p.D168D and p.G212D). 
6 out of 9 mutations with the ability to persist during OSCC evolution were detectable at 
early stage of tumorigenesis  in the non neoplastic surrounding field. Interestingly, 1 out of 6 
(NRASp.G138R)  in patient 1 was not detectable in primary tumour but was transferred 
directly to second neoplastic event in some sort of evolutionary jump. 
3 out 9 persistent mutations were not found early in non neoplastic adjacent mucosae 
(TP53 p.R273C, NOTCH1 p.G212D, KRAS p.A130Q) but developed at later stages of 
tumorigenesis. In particular TP53 p.R273C in patient 1 was found in primary tumour, it was 
transferred to second event but was not found in the third OSCC. By contrast,  in patient 2 
NOTCH1 p.G212D arose late in OSCC evolution and was found only in second neoplastic 
manifestation from which it was transferred to the third. Interestingly, in patient 4 KRAS 
p.A130Q arose after primary tumour but was transferred from second event to all 4 
subsequent  neoplastic relapses. 
In only one patient (Patient 5) persistent mutations could not be identified. (Table 20) 
 
 
Analysis of tumor evolution mtDNA phylogenetic trees: 
The analysis of phylogenetic trees, integrated data from mutational analysis and helped to 
visualize the  evolutionary connections among samples in the progression from non 
neoplastic mucosae to  recurrent events in OSCC. 
Interestingly, in 3 out of 4 patients from the group of recurrent OSCCs samples from non 
neoplastic mucosa were displayed on different branches. Heterogeneity was confirmed as 
an early process in tumorigenesis and not restricted only to tumours. In particular, in patient 
4 samples seemed to belong to distinct genetic clusters as their position on the tree was 
considerably distant. 
mtDNA analysis of multiple tumour samples tracked the evolution of subclones during 
disease progression. 
In patient 1 only one sample of primary tumour was located in proximity to samples from 
second and third adverse event, suggesting a common evolutionary line.  
In patient 3 samples from non neoplastic mucosae clustered in mutual proximity but their 
MtDNA profiles appeared evolutionarily more similar to samples from secondary adverse 
events rather than primary tumour. This pattern suggested a pivotal role of the field in 
tumour progressions and in the formation of second field tumours. (Fig.22 A,B,C,D,E) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table15. Summary of patients characteristics ( M: Male F: Female nM : months) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG.21 The figure illustrates the workflow for samples processing and data analysis: from FFPE blocks,  
selected areas were manually macrodissessected and processed for DNA and mtDNA extraction. 
Amplicon libraries for studied genes were then generated for  DNA sequencing through MiSEQ platform 
(Illumina).  
Table 16: Mutational analysis in the group 
of recurrent OSCC. For each tumour the 
number of mutations found through NGS, 
the number of mutations found in each 
sample and the number of shared mutations 
among samples are indicated. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 17  Mutational analysis in the 
group of non recurrent OSCC. 
Table 18  Heterogeneity Rate ( HR) values in 
primary tumors and related adjacent mucosa. 
Patients 1-5 ( Recurrent OSCC) Patients 5-10 ( 
Non recurrent OSCC). Mann-Whitney U test for 
independent samples was used to compare HR 
values in primary tumour and adjacent mucosa  
of the two groups ( recurrent and non recurrent 
OSCC).  
FIG.22 The figure illustrates  Heterogeneity 
Rate (HR) values in primary tumors and 
related adjacent mucosa in both groups of 
recurrent ( blue boxes) and not recurrent 
OSCC ( red boxes). P values refer to Mann-
Whitney U test for independent samples 
results. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 19  Heterogeneity Rate ( HR) 
values in second events (II-VI) after 
primary tumour (I) from the group of 
recurrent OSCC. 
TAB 20  Tracking tumour evolution through somatic mutations analysis. For each patient 
(1-10)  mutations that persisted from mucosal field (N) to neoplastic events ( I-VI) are 
highlighted 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 23: Phylogenetic trees by sequencing of mtDNA D-loop region using UPGMA for recurrent OSCC: 
A: Patient 1: only one sample of primary tumour was located in proximity to samples from second and third adverse event, 
suggesting a common evolutionary line. 
B: Patient 2: samples from non neoplastic mucosa were displayed on different branches. Heterogeneity was confirmed as an 
early process in tumorigenesis  
C: Patient 3: samples from non neoplastic mucosae clustered in mutual proximity but their MtDNA profiles appeared 
evolutionarily more similar to samples from secondary adverse events rather than primary tumour 
D: Patient 4: samples from non neoplastic mucosae seemed to belong to distinct genetic clusters as their position on the tree 
was considerably distant 
E: Patient 5: Mutational analysis did not exhibit common mutations among samples. MtDNA analysis integrated data from 
mutational analysis and helped to visualize the  evolutionary connections among samples.  
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DISCUSSION: 
Despite recent advances in OSCC treatment (radical surgery, chemotherapy and molecular 
therapy with anti-EGFR monoclonal antibodies) mortality rates did not improve 
significantly.(117) Unfavourable prognosis of OSCC frequently depends on scarce loco 
regional control. After resective surgery patients operated for OSCC tend to develop distant 
metastasis or new oral carcinomas.(96) 
The theory of field cancerization explains this aggressive behaviour. Although tumour 
adjacent  epithelium may appear clinically or histologically unaffected, unseen genetic errors  
may be responsable for disease progression.(5)  Next Generation Sequencing(NGS) 
improved  our understanding of molecular biology of OSCC and confirmed the theory of field 
cancerization. A genetic classification of secondary OSCCs was proposed by Braakhuis et 
al. and distinguished between  Local Recurrence, Second Primary Tumour and Second 
Field Tumour, whether second events were genetically proximal to index tumour, to the 
adjacent field or were genetically independent.(49) 
E 
However, deep coverage of NGS also revealed that genetic differences may exist among 
tumour cells.(56) Intratumour Heterogeneity theory states that during tumour evolution, 
under the effect of Darwinian-like pressures, cancer cells may follow distinct evolutionary 
lines.(58)  Consequently, genetically heterogeneous subclones may coexist within the 
tumour. 
In many cases genetic investigations on tumours  rely on single  biopsy samples. Due to 
intratumoral heterogeneity, a single sample may offer a narrow insight on tumour genetics 
depending on the area the specimen is taken from.(132) 
In the present study we compared genetic profiles of OSCCs obtained from one or multiple 
samples. Results showed that  the number of mutations yielded by a single sample was in 
most cases inferior to the profile revealed by two samples. In particular in both  groups of  
recurrent and non recurrent OSCC  90% of samples was less informative than the 
combination of two samples.  
The limited perspective offered by a single sample was confirmed also for secondary 
events. However, 80% of samples from the second events and 66.6% of samples from the 
third events were inferior in terms of number of mutations  to the analysis of multiple 
samples.  What apparently suggests an increase in homogeneity during disease 
progression may be the effect of selective pressures supporting clones that better survive in 
oral field microenvironment. 
In project 3 it was demonstrated that cellular heterogeneity applies not only to tumours but 
also to adjacent field. Indeed, one sample was less informative than two samples also in 
almost all cases of non neoplastic adjacent mucosa from recurrent OSCC. Curiously, similar 
results were not observed in the group of non recurrent OSCC where mutations yielded by 
samples of non neoplastic adjacent mucosa resulted more homogeneous. In particular, only 
3 out of 10 samples were less informative than the combination of two samples. 
Being molecular targeted therapy deeply influenced by  genetic profiles of tumours, 
intratumour heterogeneity represents a source of distortion that may misguide therapeutic 
strategies. 
Indeed, underdiagnosis derived from the investigation of a limited area of the tumour may 
occult mutations potentially targetable by molecular drugs. 
We investigated the occurrence of a WT/Mutated discrepancies and we found that such 
eventuality could involve all studied genes, independently from clinical behaviour. 
However, since mutations may differ among subclones a measure of ITH was essential. As 
described previously(116) we obtained a value representative of the degree of ITH  by 
calculating the heterogeneity rates (HR)  of all affected genes and dividing that sum by the 
number of affected genes not shared by all tumor regions.  
HR values of primary tumors in two groups of recurrent and non recurrent OSCCs were 
statistically compared to investigate prognostic implications of ITH.  No statistical significant 
difference was recorded among groups. According to our results no particular degree of 
heterogeneity was able to distinguish OSCC with aggressive local behaviors. Genetic 
instability in tumours may produce heterogeneous subclones but not all subclones may 
reflect aggressive behaviors. This finding is in disagreement with Mroz et al.(127,128) who 
found a relation between high intra-tumor genetic heterogeneity and worse clinical 
prognosis. Mroz et al. however, used MATH values to calculate intratumour heterogeneity, a 
measure based on whole-exome sequencing of tumors but applied to single biopsy 
specimen. (128)Differences in the methodology may explain divergent results especially if a 
multi region approach to the study of intratumour heterogeneity is not considered. 
Interestingly, ITH analysis of non neoplastic adjacent mucosa disclosed that non recurrent 
OSCC tends to exhibit statistically lower values of HR if compared to recurrent OSCCs ( p= 
0,032). Fields of less aggressive OSCCs are thus more homogeneous.  
A prognostic implication of genetic heterogeneity of pre neoplastic field is here documented 
for the first time. Hypothetically, genetic homogeneity around primary tumour could reflect 
less genetic instability of surrounding mucosae and related lower ability to harbour the 
development of aggressive mutations. 
By contrast, ITH investigated in secondary events showed that both increase or decrease in 
the degree of HR could occur during disease progression. Nevertheless, more than 50% of 
studied local relapses had ITH levels lower than related pre-existing tumour.  
Although clonal selection of more aggressive mutations could genetically explain decreasing 
values of  heterogeneity in recurrent OSCC the studied population is too limited and further 
studies are encouraged. 
Genetic relationships between the field and neoplastic events were also investigated 
through mtDNA based phylogenetic trees and the identification of persisting mutation. 
9 mutations exhibited the ability to be transferred to chronologically subsequent events. 6 
out of 9 mutations were early detectable in pre neoplastic field whereas 3 developed at later 
stages. 
Evidence of genetic links among samples from pre neoplastic field and chronologically 
subsequent events was also suggested by mtDNA analysis(i.e patient 1). This finding 
confirms Braakhuis classification of second field tumours. However, the use of mutational 
analysis in tracking tumour evolution combined with mtDNA phylogenetic trees  suggested  
a more complex landscape. In particular,  in patient 1 linear  persistence of many mutations 
from pre neoplastic field to later events seemed to suggest Braakhuis second field tumours 
but NRASp.G138R “jumped” primary tumour and was transferred directly to second 
neoplastic events. By contrast, in patient 5 mutational analysis did not identify persistent 
mutations as for Braakhuis second primary tumours but mtDNA phylogenetic tree exhibited 
apparent genetic continuity among samples from subsequent events as in local 
recurrences/second field tumours. These findings confirm that during tumour evolution 
continuing shaping of mutational profile of both fields and tumours takes place under 
microenvironment selective pressures. In a similar context, the study of intratumour 
heterogeneity through multi region analysis is a good approach for the observation of 
complex interactions between OSCC and the field.   
 
In conclusion, the degree of genetic heterogeneity of pre malignant field seems to have an 
impact on loco regional prognosis of patients operated of OSCC. Under the effect of genetic 
instability, high heterogenous fields could more easily host the development of aggressive 
mutations responsible for disease relapse. On the contrary increasing homogeneity during 
tumor progression could reflect clonal selection under the pressure of tumour-field 
microenvironment. However, due to small size of studied population and evidence of 
different patterns of tumor evolution future studies confirming our results are strongly 
encouraged. In addition, the analysis of multiple areas instead of a single specimen 
confirmed to exhibit higher reliability in describing mutational profile and should be 
acknowledged for future research, diagnostic and therapeutic strategies in the management 
of OSCC.  
 
 
 
 
 
 
 
 
 
 
 SUPPLEMENTRY MATERIALS PROJECT 4: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 21  Somatic mutations profiles in recurrent OSCCs. For each sample, related somatic mutationst in the ten 
studied genes are illustrated. ( N: adjacent Normal Mucosa Pr. Primary tumour VAF Variant allele frequency ) 
NoCaso KRAS NRAS HRAS BRAF EGFR TP53 CDKN2A AKT1 CTNNB1 PTEN NOTCH1 PIK3CA
STS N1
p.G115E VAF 10% Pd57N 
VAF 6% p.G10 R 6%    p.E132K VAF 16% C
p.G13D VAF8% C 
p.V14M VAF  9% NC 
p.G75G VAF 5% C  p.Q609 * VAF 9% c
p.F712F  VAF 15% NC 
p.R836R   VAF 18 %
p.A189A VAF 13% C 
p.P191L VAF 12% C 
p.I255I VAF 28% NC
p.A86V VAF 70%   
p.P61S 14% NC NA NA WT
p.N214F VAF 41% NC 
p.E330L VAF 21% NC 
p.E334L 21% p.G597D 
VAF 68% NC p.E606L 
VAF68% C p.D1698D 
VAF 14%Cp WT
STS N2
p.G12S  VAF 11% C p.H27Y 
VAF 12% C 
p.M1I VAF 19% C 
p.G10E VAF 11% C 
p.G138R vaf 8%  c
p.H27H VAF 84% C 
p.S65R VAF 5% nc p.Q609K vaf 11%
p.E697K  vaf 10% nc 
p.P694T   vaf 8% nc p.P 
699P vaf 10% p.L703L  
vaf 10%   p.Q787Q  vaf 
43%
p.G117R vaf 35% C 
p.S215N VAF 10% C
p.P40S (TCC) vaf 6% 
p.L78F VAF 10% NC NA NA
p.H196H(CAT) VAF 14% NC 
p.P204S (TCA)VAF7% C 
p.R233Q(CAA) VAF 9% NC 
 p.D582D VAF 25% NC 
p.R1586(TGC) vaf 5% 
p.D1698D VAF 51 % C p.N526SVAF 21% NC
STS PR1 p.V14I vaf7% C
p.E3K VAF19% NC 
p.R123R NC VAF 9% 
p.F141K VAF 24% NC
p.V7M VAF 5% NC 
p.G15C VAF7% p.T20I 
VAF 6% C p.E49E 
VAF7%NC p.A59V vaf 
11% p.S65N vaf 5% 
p.E76E VAF 7%  NC WT
p.E711K vaf 16% p.H835H   
vaf 46% p.R836R vaf 56% 
nc p.D837N  vaf 10% 
p.V851I 11% p.R841R  vaf 
10%  
p.N239N vaf 13% c 
p.L252F vaf 13% c 
p.D259D 15% p.R273C 
vaf 17% wt na na
 p.N184L(TTG) vaf 8% 
p.H196M(ATG) vaf 8% 
p.V222V(GTA) vaf 11% nc 
p.K223K(AAA) vaf 6% nc 
p.P244L(CTT) vaf 5% p.V249HV 
(GTA) vaf8% nc
p.A208V vaf 60% 
p.G326D vaf 26% 
p.S333N vaf 14% 
p.D338(AAC) vaf 12%  
p.A340T vaf 
26%p.A585V vaf 13% 
p.T602I vaf 13% 
p.S1695N vaf 7% WT
STS PR4
p.D30D vaf 6% p.E62K vaf 
11% wt p.T20I vaf 11% wt
p.R836R vaf 39% 
p.L838L(CTA) vaf 22%
p.L206L  vaf 10% 
p.G244S vaf 18% 
p.R248Q vaf 10% 
p.P322T vaf 5% p.T329I 
vaf 59%
p.L47R vaf 7% p.R51K 
vaf 21% p.R62K vaf 
18% na na
p.Q171*(tag) vaf 13% 
p.H196M(ATG) vaf 7% 
p.S229L(TTA) vaf 7% 
p.V249V(GTA) vaf 5% 
p.G251D(GAT) vaf 7%   
 p.H316H vaf 84% 
p.G597D vaf 18% WT
common 0 0 0 0 1 0 0 1 0 0
STS 2.3 WT p.G138R vaf 6% wt wt p.R836R(CGT) vaf 57% p.R273C vaf 17%  WT na na WT
p.p.C339Y vaf 5% 
p.S341N vaf 5% WT
STS 2.4 WT WT p.I24V vaf 5% NA p.R836R(CGT) vaf 46% p.R273C vaf 14% wt na na wt wt wt
COMMON 1 1 1
STS 3.1 WT p.G138R vaf 5% wt wt p.R836R(CGT) vaf 46% p.R290C vaf 5% wt na na WT
 p.V324V vaf 5% 
p.S1589S vaf 5%
STS 3.3 p.L23L vaf 25% WT WT NA p.R836(CGT) vaf 90%
p.G245S  vaf 29% 
p.R248S vaf 31% 
p.C275Y vaf 
91%p.K291R vaf 6% na na NA WT wt WT
COMUNE 0 0 0 0 1 0 0 0 0 0
NoCaso KRAS NRAS HRAS BRAF EGFR TP53 CDKN2A AKT1 CTNNB1 PTEN NOTCH1 PIK3CA
PECN1 wt wt wt na p.Q787Q(CAA) vaf 51% wt wt wt
p.G310G vaf:10% 
p.D1698D vaf:44% wt
PECN2 wt
p.V112M vaf.10% 
p.L133L vaf:30% 
p.H131N vaf:5% wt wt p.Q787Q(CAA)vaf 37% wt p.P75P vaf.5% na na wt
 p.G310G vaf 18% 
p.D1698D vaf.40% wt
COMUNE 0 0 0 0 1(1/1) 0 0 0 2 0
PEC1 wt wt wt wt wt wt wt wt wt wt p.D1698D vaf:37% wt
PEC2 wt wt wt na p.Q787Q(CAA) vaf 58% wt p.E33G vaf:20% na na wt p.D1698D vaf:37% wt
COMUNE 0 0 0 0 0 0 0 0 0 0 0 0
PEC 2.1 wt wt wt na p.Q787Q(CAA) vaf 46% p.Q192* vaf 67% wt wt
p.G212D  vaf 6% 
p.C339Y vaf 6% p.A340T 
vaf 6% p.D1698D vaf 
28% wt
PEC 2.2 WT wt WT WT p.Q787Q(CAA) vaf 72% p.G240E vaf 17% wt na na WT
p.T211(ATT) vaf 5% 
p.D337(aat) VAF 5% wt
COMUNE 0 0 0 1 0 0 0 0 0 0
PEC 3.1 WT WT WT WT p.Q787Q(CAA)  vaf 38% WT WT WT WT WT
p.G212D  vaf 6%  
p.D1698D vaf 33% WT
Pec 3.2 WT WT WT WT p.Q787Q(CAA)  vaf 38% WT WT WT WT WT WT WT
COMUNE 0 0 0 0 1(1/1) 0 0 0 0
NoCaso KRAS NRAS HRAS BRAF EGFR TP53 CDKN2A AKT1 CTNNB1 PTEN NOTCH1 PIK3CA
LAM N1 WT WT WT WT p.Q787Q(CAA) vaf 100 % WT   p.P81P vaf 7% NA NA WT
p.P213L vaf 7%  p.G326S 
vaf 6% p.D1698D vaf 
41% WT
LAM N2 WT WT WT WT
p.Q787Q(CAA) vaf 100 % 
p.L718L(TTG) vaf 5% WT   p.R54C vaf 6%  NA NA WT
 p.T1697I vaf 8% 
p.D1698D vaf 57% WT
COMUNE 0 0 0 0 1(1/2) 0 0 1
LAM 1.2 WT WT WT WT p.Q787Q(CAA) WT wt NA NA WT p.D1698D vaf 31% WT
LAM 1.3 WT WT
p.S65S vaf 6%  
p.D69D vaf 6%  NA p.Q787Q(CAA) WT  WT NA NA  WT wt WT
COMUNE 0 0 0 0 1(1/1) 0 0 0 0 0
LAM 2.1 G13D vaf 15% WT WT NA p.Q787Q(CAA) vaf 100% p.R290C vaf 11% wt NA NA WT
 p.S341N vaf 9% 
p.F1593F vaf 5% 
p.L1601L vaf 5% 
p.D1698D vaf 32% WT
LAM 2.2 p.T127T vaf 14% WT p.M67I vaf 5% NA p.Q787Q((CAA) vaf 100% WT NA NA NA WT
 p.S341N vaf 17% 
p.D1698D vaf 42% WT
COMUNE 0 0 0 0 1(1/1) 0 0 0 1
NoCaso KRAS NRAS HRAS BRAF EGFR TP53 CDKN2A AKT1 CTNNB1 PTEN NOTCH1 PIK3CA
BE N1 p.E31* VAF:23% p.G48C VAF:23% WT WT p.V742I VAF: 24% WT WT NA NA WT WT WT
BE N2 p.G48V VAF: 22% p.L56M VAF: 27% WT WT p.V845M VAF: 35% WT WT NA NA WT WT WT
BE 1 WT WT WT WT WT p.H179I VAF: 18% p.R29Q VAF:11% NA WT p.C250Y VAF:9% WT WT
BE 2 p.P34R VAF: 90% WT WT p.V600M VAF: 14% p.A750V VAF: 14% p.P295S VAF: 8% p.A42T VAF: 7% NA p.H24Y VAF:8% p.L318F VAF: 6% WT WT
BE 2.1 p.A130Q VAF: 39% WT WT WT WT p.C238Y VAF:13% WT NA WT p.V191M VAF: 28% WT WT
BE 2.2 p.A130Q VAF: 61% WT WT WT WT WT WT NA WT WT p.G1704E VAF5% WT
BE 3.1 p.A130Q VAF: 51% WT WT WT WT WT WT NA WT WT p.D1681N VAF23% WT
BE 3.2 p.A130Q VAF: 51% WT WT WT WT WT WT WT WT WT WT WT
BE 4.1 p.A130Q VAF: 42% WT WT WT WT WT WT NA WT WT p.R1594W VAF6% WT
BE 4.2 p.A130Q VAF: 42% WT WT WT WT WT WT NA WT WT WT WT
BE 5.1 p.A130Q VAF: 45% WT p.G13D VAF:16% WT WT p.R248W VAF:6% p.A44Q VAF: 10% NA WT p.E242K VAF:6% p.V1599M(VAF10%) WT
BE 5.2 p.A130Q VAF: 35% WT p.G13D VAF:18% WT WT WT WT NA WT WT p.C1685Y(VAF6%) WT
BE 6.1 p.A130Q VAF: 50% WT WT WT WT WT WT NA WT WT WT WT
BE 6.2 p.A130Q VAF: 45% WT WT WT WT WT WT NA WT WT WT WT
NoCaso KRAS NRAS HRAS BRAF EGFR TP53 CDKN2A AKT1 CTNNB1 PTEN NOTCH1 PIK3CA
MR N1 NA NA NA NA NA NA NA NA NA NA NA NA
MR N2 NA NA NA NA NA NA NA NA NA NA NA NA
MR 1 p.P34L VAF7% NA WT NA NA p.A74V VAF9% NA NA NA WT p.T1602* VAF15% WT
MR 2 WT WT WT NA NA WT NA NA NA WT p.G1704E VAF11% p.G1050S VAF7%
MR 2.1 WT WT p.G12DVAF8% WT WT p.A189TVAF11% na na na WT p.L1712F VAF7% p.E547L VAF7% 
MR 2.2 WT WT WT WT WT WT WT WT WT WT WT WT
MR 3.1 WT WT WT WT WT WT na na na WT WT p.S541F VAF8% 
MR 3.2 WT WT WT WT WT p.G279KVAF35% na na na WT WT WT
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NoCaso KRAS NRAS HRAS BRAF EGFR TP53 CDKN2A PTEN NOTCH1 PIK3CA
SEG N1
WT WT p.H27H VAF 50% WT
p.Q787Q VAF 100% 
p.794S VAF 7%
p.R156L VAF 49% 
p.L289L VAF 16% WT WT
p.V1686V 14% p.d1698D VAF 33% 
p.S1711N 14% WT
SEG N2
WT WT
p.G13R VAF9%) 
p.H27H VAF 50% WT
P.778L VAF 6% p.Q787Q 
VAF 100% p.L798L VAF 
8% WT WT WT p.d1698D VAF 37% WT
SEG 1.1 WT WT p.H27H VAF 54% WT p.Q787Q VAF 100% WT WT WT p.d1698D VAF 24%p.G1710S vaf 5% WT
SEG 1.2
WT WT WT WT
p.Q787Q VAF 100% 
p.791Q VAF 5% WT WT WT p.C215C vaf 6% p.D1698D VAF 58% WT
CAS N1 WT WT WT WT p.Q787Q VAF 100% WT WT WT p.D1698D VAF 55% WT
CAS N2 WT WT WT WT p.Q787Q VAF 100% WT WT WT p.D1698D VAF 53% WT
CAS 1.1
WT WT WT WT p.Q787Q VAF 46% 
p.Q192Q vaf 2% 
p.E198K vaf 5%
p.D84N 
vaf 5% WT p.d1698D VAF 47 p.S1708L vaf 6% WT
CAS 1.2 WT WT WT WT p.Q787Q VAF 49% WT WT WT p.D1698D) VAF 60% WT
FAL N1 WT WT p.H27H VAF 55% WT p.Q787Q VAF 45% WT WT WT p.D1698D VAF 61% WT
FAL N2
WT WT
p.H27H VAF 51% 
p.R68Q VAF 7% WT p.Q787Q VAF 43% WT WT WT p.d1698D VAF 55% WT
FAL 1.1
p.R123K VAF 
10% p.A147T 
VAF 10%
p.E63E VAF 
38% p.H27H VAF 60% WT p.Q787Q VAF 90% WT WT
p.R233Q VAF 
42% WT
p.T544I VAF 
11%
FAL 1.2 p.p140S VAF 
30% WT
p.H27H) VAF 60% 
p.V7M VAF 10% WT
p.F712F VAF 96% P.771N 
VAF 96%
p.G279R VAF 46% 
p.R282Q VAF46% 
p.S314F VAF 94% WT
p.P169L VAF 
29% p.L185L 
VAF 17%
p.D1698D VAF 55% p.A1705A VAF 
49% p.T596T VAF 96%
p.R537* VAF 
17% p.T544I 
VAF 11%
BAG N.1 WT WT WT WT p.Q787Q VAF 100% WT WT WT p.D1698D VAF 49% WT
BAG N.2 WT WT WT WT p.Q787Q VAF 100% WT WT WT p.D1698D VAF 51% WT
BAG 1.1 WT WT WT WT p.Q787Q VAF 100% WT WT WT p.D1698D VAF 47% WT
BAG 1.2 WT WT WT WT p.R836R VAF 45% p.Y236* VAF 18% WT WT WT WT
FEM N1 WT WT WT WT p.R836R VAF 45% p.Y236* VAF 27% WT WT WT WT
FEM N2
WT WT WT WT p.R836R VAF 41%
p.Y236(TAA) VAF 
31% WT WT WT WT
FEM 1.1 WT WT WT WT p.R836R VAF 40% p.Y236* VAF 51% WT WT WT WT
FEM 1.2
WT
p.A59V VAF 
38% p.H27H VAF 74% WT
p.V689V VAF 19% 
p.G696E VAF 7% p.L703F 
VAF 19% P.A755T VAF 
16% p.Q787Q VAF 66% p.M243* VAF 100% WT
p.S179S VAF 
51% p.S229S 
VAF 32% p.D1698D VAF 69% p.A208A VAF 88% WT
Table 22  Somatic mutations analysis in non recurrent OSCCs. For each sample mutations in the ten studied 
genes are illustrated. ( N: adjacent Normal Mucosa VAF Variant allele frequency) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BRAF
 p.Q609 * VAF 9% c C>T Pathogenic (score 0.99) RIC
p.V600M VAF: 14% G>A Pathogenic (score 0.98) RIC  
 
 
 
Table 22  COSMIC (cancer.sanger.ac.uk/cosmic)  analysis for biologic effects  somatic mutations  found in 
studied OSCCs and related adverse events. RIC found in Recurrent OSCC) NRIC: found in non recurrent 
OSCC) 
KRAS
p.G115E VAF 10% G>A Pathogenic (score 0.98) RIC
PD57N VAF 6% c.169G>A Pathogenic (score 0.98) RIC
p.G10 R 6%    c.28G>A Pathogenic (score 0.98) RIC
p.G12S  VAF 11% C c.34G>A Pathogenic (score 0.98) RIC
p.H27Y VAF 12% C C>T Pathogenic (score 0.98) RIC
p.V14I vaf7% C G>A UNKNOWN RIC
p.V7V vaf 5% n.c UNKNOWN RIC
p.D30D vaf 6% N.C UNKNOWN RIC
p.E62K vaf 11% G>A Pathogenic (score 0.98) RIC
p.L23L vaf 25% A>G UNKNOWN RIC
p.T50A vaf 5% c.148A>G Pathogenic (score 0.98) RIC
 p.T124I vaf 7% G>A Pathogenic (score 0.98) RIC
p.G138E vaf 7% G>A Pathogenic (score 0.98) RIC
p.V114I vaf 34% G>A Pathogenic (score 0.98) RIC
G13D vaf 15% c.38G>A Pathogenic (score 0.98) RIC
p.T127T vaf 14% n.c UNKNOWN RIC
p.V7M vaf:5% G>A Pathogenic (score 0.98) RIC
p.E31* VAF:23% n.c UNKNOWN RIC
p.G48V VAF: 22% n.c. UNKNOWN RIC
p.P34R VAF: 90% C>G Pathogenic (score 0.99) RIC
p.A130Q VAF: 39% n.c. UNKNOWN RIC
p.P34L VAF7% C>T Pathogenic (score 0.99) RIC
p.R123K VAF 10% n.c. UNKNOWN NRIC
 p.A147T VAF 10% n.c. UNKNOWN NRIC
p.P140S VAF 30% C>T Pathogenic (score 0.99) RIC
NRAS
p.E132K VAF 16% C G>A Pathogenic (score 0.98) RIC
p.M1I VAF 19% G>C Pathogenic (score 0.97) RIC
 p.G10E VAF 11% C G>A Pathogenic (score 0.91) RIC
p.G138R vaf 8%  c G>A Pathogenic (score 0.91) RIC
p.E3K VAF19% NC NC UNKNOWN RIC
p.R123R NC VAF 9% NC UNKNOWN RIC
p.F141K VAF 24% NCNC UNKNOWN RIC
p.G138R vaf 6% G>A Pathogenic (score 0.98) RIC
p.V112M vaf.10% G>A Pathogenic (score 0.98) RIC
 p.L133L vaf:30% NC UNKNOWN RIC
p.H131N vaf:5% NC UNKNOWN RIC
p.G48C VAF:23% n.c. UNKNOWN RIC
p.L56M VAF: 27% n.c. UNKNOWN RIC
p.E63E VAF 38% n.c. UNKNOWN NRIC
p.A59V VAF 38% n.c. UNKNOWN NRIC
HRAS
p.G13D VAF8% C G>A Pathogenic (score 0.97) RIC
 p.V14M VAF  9% NC NC UNKNOWN RIC
p.G75G VAF 5% C G>A Neutral RIC
p.H27H VAF 84% C T>C Neutral RIC-NRIC
p.S65R VAF 5% nc NC UNKNOWN RIC
p.V7M VAF 5% NC NC UNKNOWN RIC-NRIC
p.G15C VAF7% NC UNKNOWN RIC
p.T20I VAF 6% C C>T Pathogenic (score 1) RIC
p.E49E VAF7%NC NC UNKNOWN RIC
p.A59V vaf 11% NC UNKNOWN RIC
p.S65N vaf 5% NC UNKNOWN RIC
p.E76E VAF 7%  NC NC NEUTRAL RIC
p.I24V vaf 5% NC UNKNOWN RIC
p.S65S vaf 6% NC UNKNOWN RIC
p.D69D vaf 6% (ok) NC UNKNOWN RIC
p.M67I vaf 5% NC UNKNOWN RIC
p.G12DVAF8% G>A Pathogenic (score 0.99) RIC
p.R68Q VAF 7% G>A Pathogenic (score 0.97) NRIC
p.G13R 9 G C NRIC
EGFR
p.F712F VAF 15%  C>T NEUTRAL RIC
p.R836R VAF 18 % C>T NEUTRAL RIC-NRIC
p.P694T n.c UNKNOWN RIC
p.E697K vaf 10% n.c UNKNOWN RIC
p.P699P vaf 9% NEUTRAL RIC
p.L703L vaf 10%  NEUTRAL RIC
p.E711K vaf 16% G>A Pathogenic (score 0.97) RIC
p.Q787Q vaf 43% G>A Pathogenic (score 0.97) RIC-NRIC
 p.H835H  vaf 46% NEUTRAL RIC
p.D837N vaf 10% G>A Pathogenic (score 0.99) RIC
p.V851I vaf 11% G>A Pathogenic (score 0.99) RIC
 p.R841R vaf 10% nc G>A NEUTRAL RIC
 p.L838L vaf 22% NC UNKNOWN RIC
p.V742I VAF: 24% G>A Pathogenic (score 1.00) RIC
p.V845M VAF: 35% G>A Pathogenic (score 0.99) RIC
p.A750V VAF: 14% n.c. UNKNOWN RIC
p.794S VAF 7% n.c. UNKNOWN NRIC
p.P778L VAF 6% G>T Pathogenic (score 0.89) NRIC
p.L798L VAF 8% n.c. UNKNOWN NRIC
p.791Q VAF 5% n.c. UNKNOWN NRIC
p.F712F n.c UNKNOWN NRIC
P.771N VAF 96% n.c. UNKNOWN NRIC
p.V689V VAF 19% n.c UNKNOWN NRIC
p.G696E VAF 7% G>A Pathogenic (score 0.98) NRIC
p.L703F VAF 19% n.c UNKNOWN NRIC
p.A755T VAF 16% G>A Pathogenic (score 0.99) NRIC
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TP53
p.A189A vaf 10% C>T NEUTRAL RIC
p.P191L vaf 12% C>T Pathogenic (score 0.99) RIC
p.I255I VAF 28% C>A Pathogenic (score 0.95) RIC
p.G117R vaf 35% G>C Pathogenic (score 0.85) RIC
p.S215N VAF 10% G>A Pathogenic (score 0.99) RIC
p.N239N vaf 13% C>T Pathogenic (score 0.95) RIC
p.L252F vaf 13%  C>T Pathogenic (score 0.95) RIC
p.D259D 15% C>T Pathogenic (score 0.95) RIC
p.L206L  vaf 10% G>A NEUTRAL RIC
p.G244S vaf 18% G>A Pathogenic (score 0.99) RIC
p.R248Q vaf 10% G>A Pathogenic (score 0.98) RIC
p.P322T vaf 5% UNKNOWN RIC
p.T329I vaf 59% C>T Pathogenic (score 0.98) RIC
p.R290C vaf 5% C>T Pathogenic (score 0.98) RIC
p.G245S  vaf 29% G>A Pathogenic (score 0.98) RIC
p.R248S vaf 31% UNKNOWN RIC
p.C275Y vaf 91% G>A Pathogenic (score 0.98) RIC
p.K291R vaf 6% G>A Pathogenic (score 0.98) RIC
p.Q192* vaf 67% C>T Pathogenic (score 0.98) RIC
p.G240E vaf 17% nc UNKNOWN RIC
p.R290C vaf 11% C>T Pathogenic (score 0.98) RIC
p.H179I VAF: 18% n.c UNKNOWN RIC
p.P295S VAF: 8% C>T NEUTRAL RIC
p.C238Y VAF:13% G>A Pathogenic (score 0.99) RIC
p.R248W VAF:6% C>T Pathogenic (score 0.94) RIC
p.A74V VAF9% C>T NEUTRAL RIC
p.A189TVAF11% G>A Pathogenic (score 0.99) RIC
p.G279KVAF35% n.c. UNKNOWN RIC
p.R156L VAF 49% G>T NEUTRAL NON RIC
p.L289LVAF 16% C>T Pathogenic (score 0.97) NON RIC
p.Q192Q vaf 2% G>A UNKNOWN NON RIC
p.E198K vaf 5% G>A Pathogenic (score 0.99) NON RIC
p.G279R VAF 46% G>A Pathogenic (score 1.00) NON RIC
p.R282Q VAF46% G>A Pathogenic (score 0.98) NON RIC
p.S314F VAF 94% C>T Pathogenic (score 0.85) NON RIC
p.Y236* VAF 18% C>A Pathogenic (score 0.96) NON RIC
p.M243I VAF 100% G>A Pathogenic (score 0.97) NON RIC
NOTCH1
p.N214F    NC UNKNOWN RIC
p.E330L NC UNKNOWN RIC
p.E334L  NC UNKNOWN RIC
p.G597D  NC UNKNOWN RIC
p.E606L  NC UNKNOWN RIC
p.D1698D  C>T NEUTRAL RIC_NRIC
 p.D582D  NC UNKNOWN RIC
p.R1586C C>T Pathogenic (score 0.88) RIC
p.A208V  NC UNKNOWN RIC
 p.G326D vaf 26% G>A Pathogenic (score 0.97) RIC
p.S333N NC UNKNOWN RIC
p.D338N vaf 12% NC UNKNOWN RIC
 p.A340T vaf 26% NC NC UNKNOWN RIC
p.A585V vaf 13% NC NC UNKNOWN RIC
p.T602I vaf 13% C>T Pathogenic (score 0.85) RIC
 p.S1695N vaf 7% NC NC UNKNOWN RIC
p.H316H vaf 84% NC NC UNKNOWN RIC
p.G597D vaf 18% NC NC UNKNOWN RIC
p.C339Y vaf 5% NC NC UNKNOWN RIC
p.S341N vaf 5% NC NC UNKNOWN RIC
 p.V324V NC UNKNOWN RIC
p.S1589S vaf 5% NC NC UNKNOWN RIC
p.G310G vaf:10% NC NC UNKNOWN RIC
p.G212D(GAC) vaf 6% G>T Pathogenic (score 0.90) RIC
p.C339Y vaf 6% NC NC UNKNOWN RIC
p.A340T vaf 6% NC NC UNKNOWN RIC
p.T211 vaf 5% NC NC UNKNOWN RIC
p.D337N VAF 5% A>T Pathogenic (score 0.99) RIC
p.G212D vaf 6%  NC UNKNOWN RIC
p.P213L vaf 7%  C>T UNKNOWN RIC
p.G326S vaf 6% G>A UNKNOWN RIC
p.S341N vaf 17% NC UNKNOWN RIC
p.G1704E VAF5% n.c. UNKNOWN RIC
p.D1681N VAF23% n.c. UNKNOWN RIC
p.R1594W VAF6% n.c. UNKNOWN RIC
p.V1599M(VAF10%) n.c. UNKNOWN RIC
p.C1685Y(VAF6%) G>A Pathogenic (score 0.94) RIC
p.T1602* VAF15% n.c. UNKNOWN RIC
p.G1704E VAF11% n.c. UNKNOWN RIC
p.L1712F VAF7% n.c. UNKNOWN RIC
 p.T1697I vaf 8% n.c. UNKNOWN RIC
p.F1593F vaf 5% n.c. UNKNOWN RIC
p.L1601L vaf 5% n.c. UNKNOWN RIC
 p.A1705A VAF 49% G>A NEUTRAL NON RIC
 p.T596T VAF 96% n.c. UNKNOWN NON RIC
p.A208A VAF 88% n.c. UNKNOWN NON RIC
p.V1686V 14% NC UNKNOWN NON RIC
p.S1711N 14% NC UNKNOWN NON RIC
p.G1710S vaf 5% NC UNKNOWN NON RIC
p.C215C vaf 6% NC UNKNOWN NON RIC
p.S1708L vaf 6% NC UNKNOWN NON RIC
PIK3CA
p.N526S vaf 21% A>G UNKNOWN RIC
p.G1050S VAF7% G>A Pathogenic (score 0.97) RIC
p.E547L VAF7% nc UNKNOWN RIC
p.S541F VAF8% c>T Pathogenic (score 0.95) RIC
p.T544I VAF 11% c>T Pathogenic (score 0.97) NON RIC
p.R537* VAF 17% C>T Pathogenic (score 0.87) NON RIC
  
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY: 
ITH in Head and Neck Squamous Cell carcinoma (HNSCC) was firstly described by 
Slaugther et al. in 1953 when he proposed the theory of field cancerization in oral mucosa 
Slaughter et al. reported that within each OSCC tumour mass areas with different 
morphological features can be observed.  
This brilliant observation changed our way of studying Squamous cell carcinoma of the 
Head and Neck . The strict follow up applied to patients after surgery and all the strategies 
adopted to find useful biomarkers for disease progression are directly linked to Skaughter’s 
intuition. 
CDKN2A
p.A86V VAF 70%  C>T Pathogenic (score 0.99) RIC
 p.P61S 14% NC UNKNOWN RIC
p.P40S NC UNKNOWN RIC
 p.L78F  NC UNKNOWN RIC
p.L47R vaf 7% NC UNKNOWN RIC
p.R51K vaf 21% NC UNKNOWN RIC
p.R62K vaf 18% NC UNKNOWN RIC
p.P75P vaf.5% C>T NEUTRAL RIC
p.E33G vaf:20% NC UNKNOWN RIC
p.P81P vaf 7% C>G NEUTRAL RIC
p.R54C vaf 6%  NC UNKNOWN RIC
p.R29Q VAF:11% G>A NEUTRAL RIC
p.A42T VAF: 7% n.c. UNKNOWN RIC
p.A44Q VAF: 10% n.c. UNKNOWN RIC
PTEN
p.H196H VAF 14%  NC UNKNOWN RIC
p.P204S VAF7% C>T Pathogenic (score 0.99) RIC
p.R233Q VAF 9% NC G>A Pathogenic (score 0.99) RIC
p.N184L vaf 8% NC UNKNOWN RIC
p.H196M vaf 8% NC UNKNOWN RIC
p.V222V vaf 11% nc NC UNKNOWN RIC
p.K223K vaf 6% nc NC UNKNOWN RIC
p.P244L vaf 5% NC UNKNOWN RIC
p.V249HV  vaf8% nc NC UNKNOWN RIC
p.Q171* vaf 13%  C>T Pathogenic (score 0.99) RIC
p.H196M vaf 7% NC UNKNOWN RIC
 p.S229L vaf 7% NC UNKNOWN RIC
p.V249V vaf 5% NC UNKNOWN RIC
p.G251D vaf 7%  G>A Pathogenic (score 0.99) RIC
p.C250Y VAF:9% G>A Pathogenic (score 0.99) RIC
p.L318F VAF: 6% C>T Pathogenic (score 0.99) RIC
p.V191M VAF: 28% G>A Pathogenic (score 0.97) RIC
p.E242K VAF:6% G>A Pathogenic (score 0.99) RIC
p.R233Q VAF 42% G>A Pathogenic (score 0.97) NON RIC
p.P169L VAF 29% C>T Pathogenic (score 0.95) NON RIC
 p.L185L VAF 17% n.c. UNKNOWN NON RIC
p.S179S VAF 51% n.c. UNKNOWN NON RIC
 p.S229S VAF 32% n.c. UNKNOWN NON RIC
Neither molecular biology nor NGS technology have denied the theory of field cancerition. 
On the contrary, DNA sequencing have confirmed that Slaughter’s intuitions were correct 
and have paved the way to new landscapes of research. 
Studies in this PhD project have focused on Slaughter’s field cancerization theory and have 
investigated OSCC and related mucosal field with sophisticated biomolecular techniques. 
PROJECT 1: Ki67 labelling index was investigated in the index tumour and in the 
contralateral cheek, opposite to tumour resection. Finding a high Ki67 labeling index distant 
mucosa of patients who experienced a poor loco regional control raised two important 
concusions. Firstrly, altered field may progress extensively beyond the surgical marginal. 
Secondly, the ability of detecting the field is pivotal in order to compensate what naked eye 
cannot see. Indeed molecular study of the field may help the prognosis of the patients. At 
least, for early diagnosis of tumour recurrences. 
PROJECT2: Consequently, Tumour recurrences were  the object of further investigation. A 
genetic approach to Slaughter’s theory of field cancerization made clear that the knowledge 
of the biological nature of tumour recurrences is essential. In particular, significant 
differences may exist between a local recurrence generated by incomplete surgical 
resection and a second field tumour, a new neoplasia raised from the accumulation of new 
mutations in a mutated field. mtDNA analysis was used to investigate the phylogenetic 
relationship between adverse events. More deeply, the genetic distance between the 
tumours ( index tumour and recurrences) and two areas of the field was studied to 
distinguish between Second Primary Tumour, Second Field Tumour and local Recurrence. 
According to prognostic outcome of the studied population it could be noted that Second 
Field Tumour had the most favourable prognosis with respect to Second Primary Tumour 
and Local Recurrences. In addition, discrepancy between clinical classification of second 
events and results from mtDNA analysis was recorded. Results demonstrated that a 
biomolecular classification of tumour is important to cope with the biological complexity of 
field cancerization. 
PROJECT 3 and 4:  Nevertheless analysis were carried out using only a single tumour 
sample. As reported in the present thesis, from recent genetic studies it emerged that in 
many cancers,  differences among   tumour cells may be revealed if different areas of the 
tumour are studied. Genetic divergences are the effect of different evolutionary lines 
adopted by tumour subclones during tumour evolution.  Therefore multiple regions from 
both the index tumour, the adjacent mucosa and second events were studied. 
It emerged that Intratumour Heterogeneity ( genetic differences among tumour cells) can be 
observed also for Oral squamous Cell Carcinoma. The analysis of mtDNA also  permitted to 
track subclones that persisted from adjacent mucosa to metastasis and/or second events. 
Noteworthy, it was reported for the first  time that genetic heterogeneity can be observed 
also in adjacent non neoplastic mucosa. The term Field Heterogeneity could be therefore 
proposed.  
Consequently, the prognostic impact of genetic heterogeneity was investigated, with 
particular interest for local recurrences. It emerged that low grade of heterogeneity in 
adjacent mucosa was associated with lower risk of developing a second local neoplasia.  
The results obtained during this PhD have confirmed the theory of Slaughter for field 
cancerization effect. As clinical phenomenon it can’t be ignored for further diagnostic and 
therapeutic effect. As far as the use of Ki67 is concerned the small number of the studied 
population does not permit to support the use of Ki67 for routine practice but the low cost 
and easy application include it among the promising biomarkers to be validated at larger 
levels. Also the mtDNA analysis should benefit from larger studies. In fact it permits to track 
the phylogenesis of different subsequent events. However, the bias of genetic heterogeneity 
should not be underestimated. In fact, a single tumour sample risks of being of limited use. 
Despite the prognostic effect of the study of Field Heterogeneity seems intriguing the results 
should be taken carefully due to the limited studied population. 
Nevertheless,we believe in the future, new perspectives may emerge if the result exposed 
in the present report will be integrated with information from epigenetics and/or HPV+ 
status.. For this reasons further studies are encouraged and we hope  that our 
results,despite the limits, will  help to unveil the complexity of OSCC biology suggested by 
Slaughter in 1953. 
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